US20200101108A1 - Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling - Google Patents
Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling Download PDFInfo
- Publication number
- US20200101108A1 US20200101108A1 US16/499,762 US201816499762A US2020101108A1 US 20200101108 A1 US20200101108 A1 US 20200101108A1 US 201816499762 A US201816499762 A US 201816499762A US 2020101108 A1 US2020101108 A1 US 2020101108A1
- Authority
- US
- United States
- Prior art keywords
- cells
- cell
- car
- tyrosine kinase
- genetically engineered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 119
- 230000011664 signaling Effects 0.000 title claims description 93
- 230000002401 inhibitory effect Effects 0.000 title claims description 22
- 108091008874 T cell receptors Proteins 0.000 title description 53
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title description 53
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 437
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims abstract description 182
- 229960002448 dasatinib Drugs 0.000 claims abstract description 182
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims abstract description 146
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims abstract description 146
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims abstract description 93
- 239000002137 L01XE24 - Ponatinib Substances 0.000 claims abstract description 92
- 229960001131 ponatinib Drugs 0.000 claims abstract description 92
- 239000000203 mixture Substances 0.000 claims abstract description 43
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 95
- 210000004027 cell Anatomy 0.000 claims description 89
- 206010028980 Neoplasm Diseases 0.000 claims description 87
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims description 84
- 238000002659 cell therapy Methods 0.000 claims description 70
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 56
- 238000002560 therapeutic procedure Methods 0.000 claims description 50
- 230000014509 gene expression Effects 0.000 claims description 46
- 238000011282 treatment Methods 0.000 claims description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 201000011510 cancer Diseases 0.000 claims description 31
- 108010002350 Interleukin-2 Proteins 0.000 claims description 26
- 102000000588 Interleukin-2 Human genes 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 26
- 230000028327 secretion Effects 0.000 claims description 26
- 229940043355 kinase inhibitor Drugs 0.000 claims description 23
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 23
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 18
- 210000000987 immune system Anatomy 0.000 claims description 17
- 239000003550 marker Substances 0.000 claims description 17
- 238000011357 CAR T-cell therapy Methods 0.000 claims description 16
- 102000017578 LAG3 Human genes 0.000 claims description 16
- 101150030213 Lag3 gene Proteins 0.000 claims description 16
- 230000001988 toxicity Effects 0.000 claims description 16
- 231100000419 toxicity Toxicity 0.000 claims description 16
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 15
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 15
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 15
- 230000003915 cell function Effects 0.000 claims description 15
- 239000002246 antineoplastic agent Substances 0.000 claims description 14
- 239000003112 inhibitor Substances 0.000 claims description 14
- 230000003612 virological effect Effects 0.000 claims description 14
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 13
- 102100033467 L-selectin Human genes 0.000 claims description 13
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 11
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 230000006907 apoptotic process Effects 0.000 claims description 10
- 238000001959 radiotherapy Methods 0.000 claims description 9
- 102000036243 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Human genes 0.000 claims description 8
- 108010002481 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Proteins 0.000 claims description 8
- 208000037581 Persistent Infection Diseases 0.000 claims description 6
- 230000007423 decrease Effects 0.000 claims description 6
- 206010052015 cytokine release syndrome Diseases 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 4
- 230000036961 partial effect Effects 0.000 claims description 3
- 150000004922 Dasatinib derivatives Chemical group 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 abstract description 177
- 239000003814 drug Substances 0.000 description 44
- 239000000427 antigen Substances 0.000 description 38
- 102000036639 antigens Human genes 0.000 description 38
- 108091007433 antigens Proteins 0.000 description 38
- 229940079593 drug Drugs 0.000 description 38
- 241000699670 Mus sp. Species 0.000 description 34
- 238000001727 in vivo Methods 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 24
- 230000004044 response Effects 0.000 description 22
- 210000004881 tumor cell Anatomy 0.000 description 22
- 230000006870 function Effects 0.000 description 21
- 102000004127 Cytokines Human genes 0.000 description 20
- 108090000695 Cytokines Proteins 0.000 description 20
- 230000001256 tonic effect Effects 0.000 description 20
- 239000003981 vehicle Substances 0.000 description 20
- 239000008194 pharmaceutical composition Substances 0.000 description 19
- 239000000546 pharmaceutical excipient Substances 0.000 description 19
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 17
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 102000009076 src-Family Kinases Human genes 0.000 description 14
- 108010087686 src-Family Kinases Proteins 0.000 description 14
- 239000001963 growth medium Substances 0.000 description 12
- 235000002639 sodium chloride Nutrition 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 11
- 230000004913 activation Effects 0.000 description 10
- 230000004186 co-expression Effects 0.000 description 10
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 230000006044 T cell activation Effects 0.000 description 9
- 230000003190 augmentative effect Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 8
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 230000003389 potentiating effect Effects 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 7
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000005754 cellular signaling Effects 0.000 description 7
- 230000002354 daily effect Effects 0.000 description 7
- -1 dasatinib)) (e.g. Chemical class 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 229960003301 nivolumab Drugs 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 6
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 6
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 6
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 230000003416 augmentation Effects 0.000 description 6
- 239000012830 cancer therapeutic Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000011198 co-culture assay Methods 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 229940126585 therapeutic drug Drugs 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000006052 T cell proliferation Effects 0.000 description 5
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 5
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- 230000002238 attenuated effect Effects 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 210000004986 primary T-cell Anatomy 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 4
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 4
- 229960002105 amrinone Drugs 0.000 description 4
- 230000006023 anti-tumor response Effects 0.000 description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 108091008042 inhibitory receptors Proteins 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 201000008968 osteosarcoma Diseases 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003302 anti-idiotype Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000007541 cellular toxicity Effects 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 230000001687 destabilization Effects 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 102000034285 signal transducing proteins Human genes 0.000 description 3
- 108091006024 signal transducing proteins Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 208000007465 Giant cell arteritis Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 101150018665 MAPK3 gene Proteins 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 208000033781 Thyroid carcinoma Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- NMFHJNAPXOMSRX-PUPDPRJKSA-N [(1r)-3-(3,4-dimethoxyphenyl)-1-[3-(2-morpholin-4-ylethoxy)phenyl]propyl] (2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carboxylate Chemical compound C([C@@H](OC(=O)[C@@H]1CCCCN1C(=O)[C@@H](CC)C=1C=C(OC)C(OC)=C(OC)C=1)C=1C=C(OCCN2CCOCC2)C=CC=1)CC1=CC=C(OC)C(OC)=C1 NMFHJNAPXOMSRX-PUPDPRJKSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940124650 anti-cancer therapies Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 208000027625 autoimmune inner ear disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 206010043207 temporal arteritis Diseases 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- CLUVPFDOKIOXDZ-UHFFFAOYSA-N CC1=C(C#CC2=CN=C3C=CC=NN23)C=C(C(=O)CC2=CC=C(CN3CCN(C)CC3)C(C(F)(F)F)=C2)C=C1 Chemical compound CC1=C(C#CC2=CN=C3C=CC=NN23)C=C(C(=O)CC2=CC=C(CN3CCN(C)CC3)C(C(F)(F)F)=C2)C=C1 CLUVPFDOKIOXDZ-UHFFFAOYSA-N 0.000 description 1
- JXEIFWYMJZWNJC-UHFFFAOYSA-N CC1=CC=CC(Cl)=C1NC(=O)C1=CN=C(CC2=NC(C)=NC(N3CCN(CCO)CC3)=C2)S1 Chemical compound CC1=CC=CC(Cl)=C1NC(=O)C1=CN=C(CC2=NC(C)=NC(N3CCN(CCO)CC3)=C2)S1 JXEIFWYMJZWNJC-UHFFFAOYSA-N 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000011038 Cold agglutinin disease Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000272496 Galliformes Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000033540 T cell apoptotic process Effects 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- KZENBFUSKMWCJF-UHFFFAOYSA-N [5-[5-[5-(hydroxymethyl)-2-thiophenyl]-2-furanyl]-2-thiophenyl]methanol Chemical compound S1C(CO)=CC=C1C1=CC=C(C=2SC(CO)=CC=2)O1 KZENBFUSKMWCJF-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 201000005179 adrenal carcinoma Diseases 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000008228 bacteriostatic water for injection Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical class OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 210000000242 supportive cell Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464469—Tumor associated carbohydrates
- A61K39/464471—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- compositions and methods for preventing or reversing T cell exhaustion relate to methods of preventing or reversing T cell exhaustion by exposing T cells experiencing T cell exhaustion to particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib), or by expanding genetically engineered T cells in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib).
- tyrosine kinase inhibitors e.g., dasatinib, ponatinib
- particular tyrosine kinase inhibitors e.g., dasatinib, ponatinib
- T cells are immune cells that become activated via T cell receptor (TCR) signaling following engagement with antigen.
- TCR T cell receptor
- Physiologic activation through the T cell receptor renders T cells capable of mediating potent antitumor or anti-infective effects.
- T cells During resolution of an acute inflammatory response, a subset of activated effector T cells differentiate into long-lived memory cells.
- T cell exhaustion T cell exhaustion is characterized by marked changes in metabolic function, transcriptional programming, loss of effector function (e.g., cytokine secretion, killing capacity), and co-expression of multiple surface inhibitory receptors.
- the root cause of T cell exhaustion is persistent antigen exposure leading to continuous TCR signaling. Prevention or reversal of T cell exhaustion has been long sought as a means to enhance T cell effectiveness in patients with cancer or chronic infections.
- the present invention addresses this urgent need.
- T cells respond to the presence of foreign antigens with a wide range of responses, including the secretion of preformed and newly formed mediators, phagocytosis of particles, endocytosis, cytotoxicity against target cells, as well as cell proliferation and/or differentiation.
- T cells are a subgroup of cells which together with other immune cell types (e.g., polymorphonuclear, eosinophils, basophils, mast cells, B cells, and NK cells), constitute the cellular component of the immune system (see, e.g., U.S. Pat. No. 6,057,294; US Pat. Appl. 20050070478).
- T cells function in immune surveillance and in the elimination of foreign antigen.
- pathological conditions there is compelling evidence that T cells play a major role in the causation and propagation of disease. In these disorders, breakdown of T cell immunological tolerance, either central or peripheral is a fundamental process in the causation of autoimmune disease.
- T cell receptor (TCR) engagement and costimulatory signaling provide the critical signals that regulate T cell activation, proliferation and cytolytic functions.
- T cells respond to antigen via a polypeptide complex composed of the ligand-binding T cell receptor (TCR) disulfide-linked ⁇ and ⁇ subunits (or ⁇ and ⁇ subunits in ⁇ T cells) that have single transmembrane (TM) spans per subunit and small intracellular tails and associate non-covalently with hetero- (CD3 ⁇ and CD3 ⁇ ) and homodimeric ( ⁇ ) signaling subunits (see, e.g., Cambier J. C. Curr Opin Immunol 1992; 4:257-64).
- TCR ligand-binding T cell receptor
- TM transmembrane
- the CD3 ⁇ , ⁇ , and ⁇ chains have single Ig-family extracellular domains, single presumably ⁇ -helical TM spans, and intrinsically disordered intracellular domains of 40-60 residues, whereas each subunit has a small extracellular region (9 residues) carrying the intersubunit disulfide bond, a single presumably ⁇ -helical TM span per subunit, and a large, intrinsically disordered cytoplasmic domain of approximately 110 residues.
- An understanding of the process of TCR-mediated TM signal transduction and subsequent T cell activation, leading to T cell proliferation and differentiation, is therefore pivotal to both health and disease. Disturbance in TCR signaling can lead to inflammatory and other T cell-related disorders.
- T cells expressing chimeric antigen receptors (CARs) at high levels undergo tonic, antigen independent signaling due to receptor clustering.
- CARs chimeric antigen receptors
- Such T cells function poorly as a result of T cell exhaustion, as evidenced by high levels of PD-1, TIM-3, LAG-3, diminished antigen induced cytokine production, and excessive programmed cell death.
- Tonic signaling can be prevented by transiently decreasing CAR associated TCR signaling proteins (e.g., TCR zeta) to levels below the threshold required for tonic signaling.
- tyrosine kinase inhibitor that inhibits T cell receptor signaling
- a particular tyrosine kinase inhibitor that inhibits T cell receptor signaling e.g., a Lck tyrosine kinase inhibitor (e.g., dasatinib)
- a Src family tyrosine kinase inhibitor reduced expression of the T cell exhaustion markers and improved formation of T cell memory.
- the present invention relates to methods of preventing or reversing T cell exhaustion by transiently inhibiting T cell receptor (TCR) signaling to restore T cell function with particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib).
- TCR T cell receptor
- CAR T cells co-cultured with tumor cells in the presence of dasatinib or ponatinib exhibit attenuated activation and degranulation, fail to secrete cytokine, and display attenuated killing in response to tumor antigen.
- compositions and methods for preventing or reversing T cell exhaustion relate to methods of preventing or reversing T cell exhaustion by exposing T cells experiencing T cell exhaustion to particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib), or by expanding genetically engineered T cells in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib).
- tyrosine kinase inhibitors e.g., dasatinib, ponatinib
- particular tyrosine kinase inhibitors e.g., dasatinib, ponatinib
- the present invention provides methods for treating a subject to mitigate T cell exhaustion, the method comprising administering to the subject a therapeutically effective amount of a tyrosine kinase inhibitor.
- a tyrosine kinase inhibitor is capable of inhibiting TCR signaling and/or CAR signaling.
- the tyrosine kinase inhibitor is a Lck kinase inhibitor.
- the tyrosine kinase inhibitor is a Fyn kinase inhibitor.
- the tyrosine kinase inhibitor is a Src family tyrosine kinase inhibitor. In some embodiments, tyrosine kinase inhibitor is dasatinib or ponatinib. In some embodiments, the treatment is prophylactic.
- the treatment increases secretion of IL-2 by T cells in the subject.
- the treatment decreases apoptosis of T cells in the subject.
- the treatment decreases expression of at least one T cell exhaustion marker selected from the group consisting of PD-1, TIM-3, and LAG-3.
- the treatment increases expression of CD62L or CCR7.
- Such methods are not limited to particular manner of administration.
- multiple cycles of treatment are administered to the subject.
- the tyrosine kinase inhibitor is administered intermittently.
- the tyrosine kinase inhibitor is administered for a period of time sufficient to restore at least partial T cell function then discontinued.
- the tyrosine kinase inhibitor is administered orally.
- Such methods are not limited to a particular type or kind of subject.
- the subject is a human.
- the subject has a chronic infection or cancer.
- the present invention provides for treating an immune system related condition or disease in a subject comprising administering to the subject genetically engineered T cells and a therapeutically effective amount of a tyrosine kinase inhibitor.
- a tyrosine kinase inhibitor is capable of inhibiting TCR signaling and/or CAR signaling.
- the tyrosine kinase inhibitor is a Lck kinase inhibitor.
- the tyrosine kinase inhibitor is a Fyn kinase inhibitor.
- the tyrosine kinase inhibitor is a Src family tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is dasatinib or ponatinib. In some embodiments, the treatment is prophylactic. In some embodiments, the tyrosine kinase inhibitor and the genetically engineered T cells are administered simultaneously and/or at different time points.
- the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.
- CAR T cells genetically engineered TCR expressing T cells
- TIL tumor infiltrating lymphocyte
- Such methods are not limited to treating a specific immune system related condition or disease.
- the immune system related condition or disease is selected from cancer or an autoimmune disease or condition.
- the present invention provides methods for preventing and/or reversing toxicity related to genetically engineered T cell administered to a subject, comprising administering to the subject a therapeutically effective amount of a tyrosine kinase inhibitor.
- a tyrosine kinase inhibitor is capable of inhibiting TCR signaling and/or CAR signaling.
- the tyrosine kinase inhibitor is a Lck kinase inhibitor.
- the tyrosine kinase inhibitor is a Fyn kinase inhibitor.
- the tyrosine kinase inhibitor is a Src family tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is dasatinib or ponatinib.
- the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.
- CAR T cells genetically engineered TCR expressing T cells
- TIL tumor infiltrating lymphocyte
- the adoptive T cell therapy is a CAR T-cell therapy.
- the adoptive T cell therapy is a transduced T-cell therapy.
- the adoptive T cell therapy is a tumor infiltrating lymphocyte (TIL) therapy.
- Such methods are not limited to a particular type or kind of toxicity related to genetically engineered T cell administered to a subject.
- the toxicity related to genetically engineered T cell administered to a subject is cytokine release syndrome.
- the toxicity related to genetically engineered T cell administered to a subject is on-target off tumor toxicity or off-target off-tumor toxicity.
- the present invention provides compositions comprising a genetically engineered T cell population, wherein the genetically engineered T cell population was expanded in the presence of tyrosine kinase inhibitor.
- the tyrosine kinase inhibitor is capable of inhibiting TCR signaling and/or CAR signaling inhibitor.
- the tyrosine kinase inhibitor dasatinib or ponatinib.
- the present invention provides methods of generating a population of genetically engineered T cells resistant to T cell exhaustion, comprising expanding a population of genetically engineered T cells in the presence of a tyrosine kinase inhibitor.
- the tyrosine kinase inhibitor is capable of inhibiting TCR signaling and/or CAR signaling inhibitor.
- the tyrosine kinase inhibitor is dasatinib or ponatinib. Such methods are not limited to a specific type or kind of genetically engineered T cells.
- the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.
- TIL tumor infiltrating lymphocyte
- the present invention provides methods of treating an immune system related condition or disease in a subject undergoing an adoptive T cell therapy, comprising administering to the subject a genetically engineered T cell population that were expanded in the presence of a tyrosine kinase inhibitor.
- the tyrosine kinase inhibitor is capable of inhibiting TCR signaling inhibitor and/or CAR signaling.
- the tyrosine kinase inhibitor is a Lck kinase inhibitor.
- the tyrosine kinase inhibitor is a Fyn kinase inhibitor.
- the tyrosine kinase inhibitor is a Src family tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is dasatinib or ponatinib. In some embodiments, the immune system related condition or disease is selected from cancer or an autoimmune disease or condition.
- the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.
- CAR T cells genetically engineered TCR expressing T cells
- TIL tumor infiltrating lymphocyte
- the adoptive T cell therapy is a CAR T-cell therapy.
- the adoptive T cell therapy is a transduced T-cell therapy.
- the adoptive T cell therapy is a tumor infiltrating lymphocyte (TIL) therapy.
- the present invention contemplates that exposure of animals (e.g., humans) suffering from cancer (e.g., and/or cancer related disorders) to adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy) with genetically engineered T cell populations and compositions comprising particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) will inhibit the growth of cancer cells or supporting cells outright and/or render such cells as a population more susceptible to the cell death-inducing activity of cancer therapeutic drugs or radiation therapies.
- T cell therapies e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy
- TIL tumor infiltrating lymphocyte
- the methods result in improved therapy outcome as such particular tyrosine kinase inhibitors are capable of 1) modulating TCR signaling within the genetically engineered T cell population (e.g., decreasing expression of one or more of PD-1, TIM-3, and LAG-3; increasing expression of memory markers (e.g., CD62L or CCR7); increasing secretion of IL-2 and other cytokines), and 2) preventing and/or reversing T cell exhaustion within the genetically engineered T cell population.
- TCR signaling e.g., decreasing expression of one or more of PD-1, TIM-3, and LAG-3
- memory markers e.g., CD62L or CCR7
- IL-2 and other cytokines e.g., CD62L or CCR7
- the present invention provides methods for treating cancer (e.g., and/or cancer related disorders) with adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy) in a subject comprising administering to the subject (e.g., simultaneously and/or at different time points) genetically engineered T cells, particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib), and additional cancer therapeutic drugs or radiation therapies.
- adoptive T cell therapies e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy
- adoptive T cell therapies e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy
- adoptive T cell therapies e.g., a CAR T
- the present invention contemplates that exposure of animals (e.g., humans) suffering from cancer (e.g., and/or cancer related disorders) to adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy) with genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) will inhibit the growth of cancer cells or supporting cells outright and/or render such cells as a population more susceptible to the cell death-inducing activity of cancer therapeutic drugs or radiation therapies.
- T cell therapies e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy
- TIL tumor infiltrating lymphocyte
- the methods result in improved therapy outcome as such genetically engineered T cell populations are resistant and/or less prone to T cell exhaustion.
- adoptive T cell therapies e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy
- adoptive T cell therapies e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy
- adoptive T cell therapies e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy
- TIL tumor infiltrating lymphocyte
- the present invention contemplates that such methods (e.g., adoptive T cell therapies with genetically engineered T cell populations and compositions comprising particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib)) (e.g., adoptive T cell therapies with genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib)) satisfy an unmet need for the treatment of multiple cancer types, either when administered as monotherapy or when administered in a temporal relationship with additional agent(s), such as other cell death-inducing or cell cycle disrupting cancer therapeutic drugs or radiation therapies (combination therapies), so as to render a greater proportion of the cancer cells or supportive cells susceptible to executing the apoptosis program compared to the corresponding proportion of cells in an animal treated only with the cancer therapeutic drug or radiation therapy alone.
- additional agent(s) such as other cell death-inducing or cell
- combination treatment of animals with such methods e.g., adoptive T cell therapies with genetically engineered T cell populations and compositions comprising particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib))
- tyrosine kinase inhibitors e.g., dasatinib, ponatinib
- adoptive T cell therapies with genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors e.g., dasatinib, ponatinib
- the present invention contemplates the various combinations of them with such methods.
- a non-limiting exemplary list of cancer includes, but is not limited to, pancreatic cancer, breast cancer, prostate cancer, lymphoma, skin cancer, colon cancer, melanoma, malignant melanoma, ovarian cancer, brain cancer, primary brain carcinoma, head and neck cancer, glioma, glioblastoma, liver cancer, bladder cancer, non-small cell lung cancer, head or neck carcinoma, breast carcinoma, ovarian carcinoma, lung carcinoma, small-cell lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, bladder carcinoma, pancreatic carcinoma, stomach carcinoma, colon carcinoma, prostatic carcinoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, myeloma, multiple myeloma, adrenal carcinoma, renal cell carcinoma, endometrial carcinoma, adrenal cortex carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, choriocarcinoma, mycosis fungoides, malignant hypercalcemia
- FIG. 1 Characterization of the GD2.28z.FKBP CAR.
- T cells were transduced with lentivirus encoding the GD2.28z.FKBP CAR on day 1 after activation and subsequently cultured with various concentrations of shield-1 in the growth medium. On day 7, CAR expression was quantified via FACS.
- FIG. 2 Removal of S1 from culture medium results in reversal of T cell exhaustion marker surface expression.
- FIG. 3 Removal of S1 from culture medium results in maintenance of CD62L expression and prevention of apoptosis.
- FIG. 4 Removal of S1 from culture medium results in reversal of function T cell exhaustion.
- FIG. 5 Removal of surface CAR results in more effective prevention of T cell exhaustion compared PD-1/PDL-1 blockade.
- FIG. 6 Removal of surface CAR rescues exhaustion in PD-1/TIM-3/LAG-3 triple positive CAR T cells after only 4 days.
- FIG. 7 Dasatinib inhibits cytokine secretion of CAR T cells in response to tumor antigen.
- FIG. 8 Dasatinib reverses exhaustion marker expression and co-expression.
- FIG. 9 Dasatinib treatment results in maintenance of CD62L expression.
- FIG. 10 Dasatinib Treatment results in augmented IL-2 and IFN ⁇ secretion in response to tumor antigen.
- FIG. 11 CAR T cells co-cultured with tumor cells in the presence of dasatinib or ponatinib exhibit attenuated activation and degranulation.
- CD19.28z CAR T cells were cultured in the presence or absence of various concentrations of dasatinib or ponatinib for at least 48 hours.
- CAR T cells were then co-cultured with CD19-bearing Nalm6 tumor cells for 6 hours.
- CD69 and CD107a surface expression was subsequently assessed via FACS.
- Plots display cells gated on the CD8+ CAR+ population.
- FIG. 12 CAR T cells co-cultured with tumor cells in the presence of dasatinib or ponatinib fail to secrete cytokine.
- high affinity GD2.28z (HA-GD2.28z) CAR T cells were co-cultured with GD2-overexpressing nalm6 for 24 hours in the presence of absence of various concentrations of dasatinib or ponatinib. Supernatant was then collected and analyzed for IL-2 and IFN ⁇ via ELISA.
- FIG. 13 CAR T cells cultured in the presence of dasatinib display attenuated killing in response to tumor antigen.
- An incucyte assay was conducted in which CD19.BBz CAR T cells were co-cultured with nalm6 tumor cells expressing a GFP reporter for 72 hours in the presence of 1 uM dasatinib or vehicle (DMSO). Tumor GFP fluorescence was measured over time. GFP values were normalized to the fluorescence intensity at the first time point.
- FIGS. 11, 12 and 13 demonstrate that dasatinib or ponatinib could serve as a rapid and reversible safety “OFF” switch for CAR T cells that are having deleterious effects in a given patient.
- FIG. 14 Dasatinib potently inhibits the phosphorylation of CAR CD3z as well as distal signaling proteins after CAR crosslinking.
- 2E6 HA-GD2.28z CAR T cells cultured in 1 uM dasatinib or vehicle were removed from culture on day 10 post-activation. Idiotype primary antibody and a crosslinking secondary antibody were then added to the cells at 5 ug/mL to initiate signaling through the CAR.
- FIG. 15 Tonically signaling CART cells expanded in the presence of dasatinib exhibit a reduction in canonical exhaustion marker expression in a dose-dependent manner.
- HA-GD2.28z CART cells were expanded in the presence of various concentrations of dasatinib or vehicle (DMSO).
- DMSO vehicle
- FIG. 15A CAR+ T cell canonical exhaustion marker expression.
- FIG. 15B CAR+ CD4+ (left) or CAR+ CD8+ (right) exhaustion marker co-expression.
- FIG. 16 Tonically signaling CAR T cells expanded in the presence of dasatinib retain the capacity to form memory.
- CD19.28z or HA-GD2.28z were expanded in the presence or absence of 1 uM dasatinib or vehicle (DMSO).
- DMSO vehicle
- FIG. 16 Tonically signaling CAR T cells expanded in the presence of dasatinib retain the capacity to form memory.
- CD19.28z or HA-GD2.28z were expanded in the presence or absence of 1 uM dasatinib or vehicle (DMSO).
- DMSO dasatinib
- FIG. 16 Tonically signaling CAR T cells expanded in the presence of dasatinib retain the capacity to form memory.
- CD19.28z or HA-GD2.28z were expanded in the presence or absence of 1 uM dasatinib or vehicle (DMSO).
- DMSO dasatinib
- FIG. 16 Tonically signaling CAR T cells expanded in the presence of dasatinib retain the capacity
- FIG. 17 Tonically signaling CAR T cells expanded in the presence of dasatinib display augmented cytokine secretion in response to tumor antigen.
- HA-GD2.28z CAR T cells were expanded in the presence or absence of various concentrations of dasatinib or ponatinib.
- Drug was removed from the T cells 24 hours prior to co-culture with GD2-overexpressing nalm6 tumor cells in order to allow the T cells to regain the ability to signal in response to tumor. After 24 hours, supernatants were collected and IL-2 and IFN ⁇ secretion was assessed via ELISA.
- FIGS. 11, 12, 13, 15 and 16 demonstrate that dasatinib and ponatinib can inhibit CART cell signaling and function.
- FIG. 17 shows that expansion of tonically signaling HA-GD2.28z CART cells in the presence of these drugs followed by remove of the drugs prior to co-culturing with tumor cells results in augmentation of IL-2 and IFN ⁇ .
- FIG. 18 Tonically signaling CART cells expanded in the presence of dasatinib display augmented cytotoxicity.
- HA-GD2.28z CAR T cells were expanded in the presence or absence of dasatinib or vehicle (DMSO) for 96 hours.
- dasatinib was removed from the T cells 24 hours prior to an incucyte assay in which T cells were co-cultured at a 1:8 E:T ratio with GD2-overexpressing nalm6 tumor.
- Tumor GFP fluorescence was measured over time. GFP values were normalized to the fluorescence intensity at the first time point.
- FIG. 19 GD2-overexpressing Nalm6 in the presence and absence of dasatinib.
- 0.5E6 143B tumor cells were engrafted intramuscularly in the legs of mice.
- 10E6 GD2.BBz CART cells expanded in the presence of dasatinib or vehicle (DMSO) were infused into mice intravenously.
- FIGS. 19 and 20 recapitulate the findings from FIGS. 14, 15, 16 and 17 in an in vivo setting. Culturing different types of CARs (GD2.BBz, HA-GD2.28z) in dasatinib and then infusing them in vivo augments their anti-tumor function.
- FIG. 20A 0.5E6 143B tumor cells were engrafted intramuscularly in the legs of mice.
- 10E6 HA-GD2.28z CAR T cells expanded in the presence of dasatinib or vehicle (DMSO) were infused into mice intravenously.
- FIGS. 19 and 20 recapitulate the findings from FIGS. 14, 15, 16 and 17 in an in vivo setting. Culturing different types of CARs (GD2.BBz, HA-GD2.28z) in dasatinib and then infusing them in vivo augments their anti-tumor function.
- FIGS. 19 and 20 recapitulate the findings from FIGS. 14, 15, 16 and 17 in an in vivo setting. Culturing different types of CARs (GD2.BBz, HA-GD2.28z) in dasatinib and then infusing them in vivo augments their anti-tumor function.
- FIG. 21 demonstrates one of the mechanisms by which dasatinib augments function.
- CAR T cells After infusing dasatinib-treated CAR T cells into mice, blood samples were taken and the number of circulating CAR T cells analyzed, a typical readout for in vivo CAR T cell proliferation in response to tumor.
- the vehicle HA-GD2.28z CAR T cells did not exhibit significantly more in vivo proliferation than mock T cells, as these cells were likely exhausted when they were initially infused into the mice.
- CAR T cells that were expanded in dasatinib retained their anti-tumor function and thus proliferated robustly in vivo.
- FIG. 22A ,B,C,D,E In vivo dasatinib treatment suppresses exhaustion marker expression, augments memory formation, and facilitates cell survival/proliferation.
- Mice were engrafted with 1E6 GD2-overexpressing nalm6 tumor cells via intravenous injection. On day 4 post-engraftment, 2E6 HA-GD2.28z CAR T cells were infused into mice intravenously. Mice were dosed with 50 mg/kg dasatinib via intraperitoneal injection on days 21-23 post-tumor engraftment.
- C CAR+ T cells constituted a higher percentage of total circulating cells (A) or total splenic cells (C) in the mouse treated with dasatinib versus the vehicle control.
- FIG. 23 The nucleic acid and amino acid sequence for CD19.28z (FMC63 scFv).
- FIG. 24 The nucleic acid and amino acid sequence for CD19.BBz (FMC63 scFv).
- FIG. 25 The nucleic acid and amino acid sequence for GD2.BBz (14G2a scFv).
- FIG. 26 The nucleic acid and amino acid sequence for HA-GD2.28z (High affinity 14G2a scFv).
- chimeric antigen receptor refers to an artificial T cell receptor that is engineered to be expressed on an immune effector cell and specifically bind an antigen.
- CARs may be used as a therapy with adoptive cell transfer. T cells are removed from a patient and modified so that they express the receptors specific to a particular form of antigen. In some embodiments, the CARs have been expressed with specificity to a tumor associated antigen, for example. CARs may also comprise an intracellular activation domain, a transmembrane domain and an extracellular domain comprising a tumor associated antigen binding region.
- the specificity of CAR designs may be derived from ligands of receptors (e.g., peptides).
- a CAR can target cancers by redirecting the specificity of a T cell expressing the CAR specific for tumor associated antigens.
- “Pharmaceutically acceptable excipient or carrier” refers to an excipient that may optionally be included in the compositions of the invention and that causes no significant adverse toxicological effects to the patient.
- “Pharmaceutically acceptable salt” includes, but is not limited to, amino acid salts, salts prepared with inorganic acids, such as chloride, sulfate, phosphate, diphosphate, bromide, and nitrate salts, or salts prepared from the corresponding inorganic acid form of any of the preceding, e.g., hydrochloride, etc., or salts prepared with an organic acid, such as malate, maleate, fumarate, tartrate, succinate, ethylsuccinate, citrate, acetate, lactate, methanesulfonate, benzoate, ascorbate, para-toluenesulfonate, palmoate, salicylate and stearate, as well as estolate, gluceptate and lactobionate salts.
- salts containing pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonium (including substituted ammonium).
- T cell refers to T lymphocytes as defined in the art and is intended to include thymocytes, immature T lymphocytes, mature T lymphocytes, resting T lymphocytes, or activated T lymphocytes.
- the T cells can be CD4 + T cells, CD8 + T cells, CD4 + CD8 + T cells, or CD4 ⁇ CD8 ⁇ cells.
- the T cells can also be T helper cells, such as T helper 1 (TH1), or T helper 2 (TH2) cells, or TH17 cells, as well as cytotoxic T cells, regulatory T cells, natural killer T cells, na ⁇ ve T cells, memory T cells, or gamma delta T cells.
- the T cells can be a purified population of T cells, or alternatively the T cells can be in a population with cells of a different type, such as B cells and/or other peripheral blood cells.
- the T cells can be a purified population of a subset of T cells, such as CD4 + T cells, or they can be a population of T cells comprising different subsets of T cells.
- the T cells are T cell clones that have been maintained in culture for extended periods of time. T cell clones can be transformed to different degrees.
- the T cells are a T cell clone that proliferates indefinitely in culture.
- the T cells are primary T cells.
- the term “primary T cells” is intended to include T cells obtained from an individual, as opposed to T cells that have been maintained in culture for extended periods of time.
- primary T cells are particularly peripheral blood T cells obtained from a subject.
- a population of primary T cells can be composed of mostly one subset of T cells.
- the population of primary T cells can be composed of different subsets of T cells.
- the T cells can be from previously stored blood samples, from a healthy individual, or alternatively from an individual affected with a condition.
- the condition can be an infectious disease, such as a condition resulting from a viral infection, a bacterial infection or an infection by any other microorganism, or a hyperproliferative disease, such as cancer like melanoma.
- the T cells are from a subject suffering from or susceptible to an autoimmune disease or T-cell pathologies.
- the T cells can be of human origin, murine origin or any other mammalian species.
- T cell exhaustion refers to loss of T cell function, which may occur as a result of an infection or a disease. T cell exhaustion is associated with increased expression of PD-1, TIM-3, and LAG-3, apoptosis, and reduced cytokine secretion.
- terapéuticaally effective dose or amount of an inhibitor of TCR signaling is intended an amount that, when administered as described herein, brings about a positive therapeutic response in treatment of T cell exhaustion, such as restored T cell function.
- Improved T cell function may include decreased expression of PD-1, TIM-3, and LAG-3, maintenance of memory markers (e.g., CD62L or CCR7), prevention of apoptosis, and increased secretion of IL-2 and other cytokines.
- the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, the particular drug or drugs employed, mode of administration, and the like. An appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation, based upon the information provided herein.
- subject refers to any vertebrate subject, including, without limitation, humans and other primates, including non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like.
- the term does not denote a particular age. Thus, both adult and newborn individuals are intended to be covered.
- the invention is based on the discovery that transient inhibition or modulation of TCR signaling and/or CAR signaling in human T cells can prevent or reverse T cell exhaustion and restore T cell function.
- the inventors have shown that GD2-CAR expressing T cells develop functional exhaustion, exhibited by expression of PD-1, TIM-3, and LAG-3 exhaustion markers. Cessation of tonic signaling restores the ability of T cells to secrete IL-2 in response to tumor antigen.
- the inventors further showed that treatment with dasatinib, a Lck tyrosine kinase inhibitor that inhibits T cell receptor signaling, reduced expression of the T cell exhaustion markers and improved preservation of T cell memory.
- Protein tyrosine kinases are a family of enzymes catalysing the transfer of the terminal phosphate of adenosine triphosphate to tyrosine residues in protein substrates. Phosphorylation of tyrosine residues on protein substrates leads to transduction of intracellular signals which regulate a wide variety of intracellular processes such as growth and activation of cells of the immune system, e.g. T-cells. As T-cell activation is implicated in a number of inflammatory conditions and other disorders of the immune system (e.g. autoimmune diseases), modulation of the activity of protein tyrosine kinases appears to be an attractive route to the management of inflammatory diseases. A large number of protein tyrosine kinases have been identified which may be receptor protein tyrosine kinases, e.g. the insulin receptor, or non-receptor protein tyrosine kinases.
- receptor protein tyrosine kinases e.g. the insulin receptor,
- Protein tyrosine kinases of the Src family have been found to be particularly important for intracellular signal transduction related to inflammatory responses (see, e.g., D. Okutani et al., Am. J. Physiol. Lung Cell Mol. Physiol. 291, 2006, pp. L129-L141; CA. Lowell, Mol. Immunol. 41, 2004, pp. 631-643). While some of Src family protein tyrosine kinases, e.g. Src, Yes and Fyn, are expressed in a variety of cell types and tissues, the expression of others is restricted to specific cell types, e.g. hematopoietic cells.
- the protein tyrosine kinase Lck is expressed almost exclusively in T-cells as the first signalling molecule to be activated downstream of the T-cell receptor, and its activity is essential for T-cell signal transduction.
- Expression of Hck, Lyn and Fgr is increased by inflammatory stimuli such as LPS in mature monocytes and macrophages.
- gene expression of the main B-cell Src family kinases, namely Lyn, Fyn and BIk is disrupted, immature B-cells are prevented from developing into mature B-cells.
- Src family kinases have also been identified as essential for the recruitment and activation of monocytes, macrophages and neutrophils as well as being involved in the inflammatory response of tissue cells.
- Lck p56 lck or lymphocyte specific kinase
- NK natural killer
- the invention is further based on the discovery that the Lck kinase inhibitor dasatinib and the receptor tyrosine kinase inhibitor ponatinib have the potential to address several important challenges currently facing the field of adoptive T cell therapies (e.g., CART cell therapies).
- these drugs were shown to potently inhibit CAR signaling, which provides a method to regulate CAR activity and thus mitigate CAR T cell toxicity while preserving the option to continue therapy once the toxicity has resolved, as the inhibitory effect of dasatinib and ponatinib on CAR T cell function is reversible.
- compositions and methods for preventing or reversing T cell exhaustion relate to methods of preventing or reversing T cell exhaustion by exposing T cells experiencing T cell exhaustion to particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib), or by expanding genetically engineered T cells in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib).
- tyrosine kinase inhibitors e.g., dasatinib, ponatinib
- particular tyrosine kinase inhibitors e.g., dasatinib, ponatinib
- the present invention contemplates that exposure of animals (e.g., humans) undergoing adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy) with genetically engineered T cell populations to compositions comprising particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) will result in improved therapy outcome as such particular tyrosine kinase inhibitors are capable of 1) modulating TCR signaling within the genetically engineered T cell population (e.g., decreasing expression of one or more of PD-1, TIM-3, and LAG-3; increasing expression of memory markers (e.g., CD62L or CCR7); increasing secretion of IL-2 and other cytokines), and 2) preventing and/or reversing T cell exhaustion within the genetically engineered T cell population.
- adoptive T cell therapies e.g., a CAR
- the present invention contemplates that the use of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) (e.g., Src family kinase inhibitors) (e.g., Lck inhibitors) within adoptive T cell therapies satisfies an unmet need as the effectiveness of such therapies are frequently compromised by such T cell populations experiencing T cell exhaustion.
- tyrosine kinase inhibitors e.g., dasatinib, ponatinib
- Src family kinase inhibitors e.g., Lck inhibitors
- the present invention provides methods for treating an immune system related condition or disease (e.g., cancer) in a subject comprising administering to the subject (e.g., simultaneously and/or at different time points) genetically engineered T cells and particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib).
- an immune system related condition or disease e.g., cancer
- administering e.g., simultaneously and/or at different time points
- genetically engineered T cells and particular tyrosine kinase inhibitors e.g., dasatinib, ponatinib.
- the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.
- CAR T cells genetically engineered TCR expressing T cells
- TIL tumor infiltrating lymphocyte
- T cells configured for transduced T-cell therapy
- viral specific T cells reengineered with a TCR or CAR include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.
- TIL tumor infiltrating lymphocyte
- Such tyrosine kinase inhibitors may be administered by any suitable mode of administration, but is typically administered orally. Multiple cycles of treatment may be administered to a subject. In certain embodiments, the tyrosine kinase inhibitors are administered according to a daily dosing regimen or intermittently. In another embodiment, the tyrosine kinase inhibitors are administered for a period of time sufficient to restore at least partial T cell function, then discontinued.
- the present invention contemplates that ex vivo expansion of a population of T cells with particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) will result in a population T cells that are resistant and/or less prone to T cell exhaustion.
- the present invention provides compositions comprising a population of T cells that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) (e.g., Src family kinase inhibitors) (e.g., Lck inhibitors).
- the present invention provides methods of expanding a population of T cells to generate T cell populations that are resistant and/or less prone to T cell exhaustion through expanding such T cells in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib).
- tyrosine kinase inhibitors e.g., dasatinib, ponatinib.
- kits comprising T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) and additional agents (e.g., additional agents useful in expanding T cells) (e.g., additional agents useful in adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy).
- additional agents e.g., additional agents useful in expanding T cells
- additional agents useful in adoptive T cell therapies e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy.
- TIL tumor infiltrating lymphocyte
- the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.
- CAR T cells genetically engineered TCR expressing T cells
- TIL tumor infiltrating lymphocyte
- T cells configured for transduced T-cell therapy
- viral specific T cells reengineered with a TCR or CAR include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.
- TIL tumor infiltrating lymphocyte
- the present invention contemplates that ex vivo expansion of a population of genetically engineered T cells (e.g., genetically engineered for use within adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy)) with particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) (e.g., Src family kinase inhibitors) (e.g., Lck inhibitors) will result in genetically engineered T cells that are resistant and/or less prone to T cell exhaustion.
- adoptive T cell therapies e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy
- TIL tumor infiltrating lymphocyte
- tyrosine kinase inhibitors e.g., dasatinib,
- compositions comprising a population of genetically engineered T cells that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib).
- tyrosine kinase inhibitors e.g., dasatinib, ponatinib.
- the present invention provides methods of expanding a population of genetically engineered T cells to generate genetically engineered T cell populations that are resistant and/or less prone to T cell exhaustion through expanding such T cells in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib).
- kits comprising genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib).
- tyrosine kinase inhibitors e.g., dasatinib, ponatinib
- Such methods are not limited to a specific type or kind of genetically engineered T cells.
- the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.
- TIL tumor infiltrating lymphocyte
- the present invention contemplates that exposure of animals (e.g., humans) undergoing adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy) with genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) will result in improved therapy outcome as such genetically engineered T cell populations are resistant and/or less prone to T cell exhaustion.
- adoptive T cell therapies e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy
- TIL tumor infiltrating lymphocyte
- the present invention provides methods of treating an immune system related condition or disease (e.g., cancer) in a subject comprising administering a population of genetically engineered T cells expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) (e.g., Src family kinase inhibitors) (e.g., Lck inhibitors).
- tyrosine kinase inhibitors e.g., dasatinib, ponatinib
- Src family kinase inhibitors e.g., Lck inhibitors
- the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.
- CAR T cells genetically engineered TCR expressing T cells
- TIL tumor infiltrating lymphocyte
- T cells configured for transduced T-cell therapy
- viral specific T cells reengineered with a TCR or CAR include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.
- TIL tumor infiltrating lymphocyte
- Such embodiments are not limited to a particular type or kind of an immune system related condition or disease.
- the immune system related condition or disease is an autoimmune disease or condition (e.g., Acquired Immunodeficiency Syndrome (AIDS), alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune lymphoproliferative syndrome (ALPS), autoimmune thrombocytopenic purpura (ATP), Behcet's disease, cardiomyopathy, celiac sprue-dermatitis hepetiformis; chronic fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy (CIPD), cicatricial pemphigold, cold agglutinin disease, crest syndrome, Crohn's disease, Degos' disease, dermatomyositis-juvenile, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia-
- AIDS Acquired
- the immune system related condition or disease is cancer (e.g., breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colorectal cancer, renal cancer, liver cancer, brain cancer, lymphoma, leukemia, lung cancer, and thyroid carcinoma).
- cancer e.g., breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colorectal cancer, renal cancer, liver cancer, brain cancer, lymphoma, leukemia, lung cancer, and thyroid carcinoma.
- the present invention contemplates that the use of genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) within adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy) satisfies an unmet need as such therapies are frequently compromised by such T cell populations experiencing T cell exhaustion.
- tyrosine kinase inhibitors e.g., dasatinib, ponatinib
- adoptive T cell therapies e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy
- TIL tumor infiltrating lymphocyte
- Such methods are not limited to a specific type or kind of genetically engineered T cells.
- the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.
- CAR T cells genetically engineered TCR expressing T cells
- TIL tumor infiltrating lymphocyte
- T cells configured for transduced T-cell therapy
- viral specific T cells reengineered with a TCR or CAR include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.
- TIL tumor infiltrating lymphocyte
- the embodiments of the present invention are not limited to specific types of tyrosine kinase inhibitors.
- the tyrosine kinase inhibitors are a Lck tyrosine kinase inhibitors.
- the tyrosine kinase inhibitor is a Src family kinase inhibitor (e.g., Src kinase inhibitor, Yes kinase inhibitor, Fyn kinase inhibitor, Fgr kinase inhibitor, Lck kinase inhibitor, Hck kinase inhibitor, Blk kinase inhibitor, Lyn kinase inhibitor).
- the tyrosine kinase inhibitor is dasatinib
- the tyrosine kinase inhibitor is ponatinib
- Some embodiments of the present invention provide for administering such methods (e.g., adoptive T cell therapies with genetically engineered T cell populations and compositions comprising particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib)) (e.g., adoptive T cell therapies with genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib)) in combination with an effective amount of at least one additional therapeutic agent (including, but not limited to, chemotherapeutic antineoplastics, apoptosis-modulating agents, antimicrobials, antivirals, antifungals, and anti-inflammatory agents) and/or therapeutic technique (e.g., surgical intervention, and/or radiotherapies).
- the additional therapeutic agent(s) is an anticancer agent.
- Tyrosine kinase inhibitors can be formulated into pharmaceutical compositions optionally comprising one or more pharmaceutically acceptable excipients.
- excipients include, without limitation, carbohydrates, inorganic salts, antimicrobial agents, antioxidants, surfactants, buffers, acids, bases, and combinations thereof.
- Excipients suitable for injectable compositions include water, alcohols, polyols, glycerine, vegetable oils, phospholipids, and surfactants.
- a carbohydrate such as a sugar, a derivatized sugar such as an alditol, aldonic acid, an esterified sugar, and/or a sugar polymer may be present as an excipient.
- carbohydrate excipients include, for example: monosaccharides, such as fructose, maltose, galactose, glucose, D-mannose, sorbose, and the like; disaccharides, such as lactose, sucrose, trehalose, cellobiose, and the like; polysaccharides, such as raffinose, melezitose, maltodextrins, dextrans, starches, and the like; and alditols, such as mannitol, xylitol, maltitol, lactitol, xylitol, sorbitol (glucitol), pyranosyl sorbitol, myoinositol, and the like.
- the excipient can also include an inorganic salt or buffer such as citric acid, sodium chloride, potassium chloride, sodium sulfate, potassium nitrate, sodium phosphate monobasic, sodium phosphat
- a surfactant can be present as an excipient.
- exemplary surfactants include: polysorbates, such as “Tween 20” and “Tween 80,” and pluronics such as F68 and F88 (BASF, Mount Olive, N.J.); sorbitan esters; lipids, such as phospholipids such as lecithin and other phosphatidylcholines, phosphatidylethanolamines (although preferably not in liposomal form), fatty acids and fatty esters; steroids, such as cholesterol; chelating agents, such as EDTA; and zinc and other such suitable cations.
- Acids or bases can be present as an excipient in the pharmaceutical composition.
- acids that can be used include those acids selected from the group consisting of hydrochloric acid, acetic acid, phosphoric acid, citric acid, malic acid, lactic acid, formic acid, trichloroacetic acid, nitric acid, perchloric acid, phosphoric acid, sulfuric acid, fumaric acid, and combinations thereof.
- Suitable bases include, without limitation, bases selected from the group consisting of sodium hydroxide, sodium acetate, ammonium hydroxide, potassium hydroxide, ammonium acetate, potassium acetate, sodium phosphate, potassium phosphate, sodium citrate, sodium formate, sodium sulfate, potassium sulfate, potassium fumerate, and combinations thereof.
- the amount of the tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) (e.g., when contained in a drug delivery system) in the pharmaceutical composition will vary depending on a number of factors, but will optimally be a therapeutically effective dose when the composition is in a unit dosage form or container (e.g., a vial).
- a therapeutically effective dose can be determined experimentally by repeated administration of increasing amounts of the composition in order to determine which amount produces a clinically desired endpoint.
- the amount of any individual excipient in the pharmaceutical composition will vary depending on the nature and function of the excipient and particular needs of the composition. Typically, the optimal amount of any individual excipient is determined through routine experimentation, i.e., by preparing compositions containing varying amounts of the excipient (ranging from low to high), examining the stability and other parameters, and then determining the range at which optimal performance is attained with no significant adverse effects. Generally, however, the excipient(s) will be present in the composition in an amount of about 1% to about 99% by weight, preferably from about 5% to about 98% by weight, more preferably from about 15 to about 95% by weight of the excipient, with concentrations less than 30% by weight most preferred.
- the pharmaceutical compositions encompass all types of formulations and in particular those that are suited for injection, e.g., powders or lyophilates that can be reconstituted with a solvent prior to use, as well as ready for injection solutions or suspensions, dry insoluble compositions for combination with a vehicle prior to use, and emulsions and liquid concentrates for dilution prior to administration.
- suitable diluents for reconstituting solid compositions prior to injection include bacteriostatic water for injection, dextrose 5% in water, phosphate buffered saline, Ringer's solution, saline, sterile water, deionized water, and combinations thereof.
- solutions and suspensions are envisioned. Additional preferred compositions include those for oral, ocular, or localized delivery.
- compositions herein can also be housed in a syringe, an implantation device, or the like, depending upon the intended mode of delivery and use.
- pharmaceutical compositions comprising one or more tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) described herein are in unit dosage form, meaning an amount of a conjugate or composition of the invention appropriate for a single dose, in a premeasured or pre-packaged form.
- compositions herein may optionally include one or more additional agents, or may be combined with one or more additional agents, such as other drugs for treating T cell exhaustion (e.g., anti-PD-1 checkpoint inhibitor, such as nivolumab), or other medications used to treat a subject for an infection or disease associated with T cell exhaustion (e.g., antiviral, antibiotic, or anti-cancer drugs and therapies, including adoptive T cell therapies).
- additional agents such as other drugs for treating T cell exhaustion (e.g., anti-PD-1 checkpoint inhibitor, such as nivolumab), or other medications used to treat a subject for an infection or disease associated with T cell exhaustion (e.g., antiviral, antibiotic, or anti-cancer drugs and therapies, including adoptive T cell therapies).
- Compounded preparations may be used including at least one tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) and one or more other agents, such as other drugs for treating T
- such agents can be contained in a separate composition from the composition comprising a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) and co-administered concurrently, before, or after the composition comprising a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib).
- a tyrosine kinase inhibitor e.g., dasatinib, ponatinib
- a tyrosine kinase inhibitor e.g., dasatinib, ponatinib
- At least one therapeutically effective cycle of treatment with a tyrosine kinase inhibitor will be administered to a subject for treatment of T cell exhaustion.
- a tyrosine kinase inhibitor e.g., a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib)
- therapeutically effective cycle of treatment is intended a cycle of treatment that when administered, brings about a positive therapeutic response with respect to treatment of an individual for T cell exhaustion.
- a cycle of treatment with a tyrosine kinase inhibitor e.g., dasatinib, ponatinib
- restores T cell function when administered transiently as described herein, restores T cell function.
- a therapeutically effective dose or amount of a tyrosine kinase inhibitor may decrease expression of PD-1, TIM-3, and LAG-3, improve maintenance of memory markers (e.g., CD62L or CCR7), prevent apoptosis, and increase secretion of IL-2 and other cytokines.
- memory markers e.g., CD62L or CCR7
- multiple therapeutically effective doses of pharmaceutical compositions comprising one or more tyrosine kinase inhibitors (e.g., dasatinib, ponatinib), and/or one or more other therapeutic agents, such as other drugs for treating T cell exhaustion (e.g., anti-PD-1 checkpoint inhibitor, such as nivolumab), or other medications used to treat a subject for an infection or disease associated with T cell exhaustion (e.g., antiviral, antibiotic, or anti-cancer drugs and therapies, including adoptive T cell therapies) will be administered.
- the pharmaceutical compositions of the present invention are typically, although not necessarily, administered orally, via injection (subcutaneously, intravenously, or intramuscularly), by infusion, or locally.
- Additional modes of administration are also contemplated, such as topical, intralesion, intracerebral, intracerebroventricular, intraparenchymatous, pulmonary, rectal, transdermal, transmucosal, intrathecal, pericardial, intra-arterial, intraocular, intraperitoneal, and so forth.
- the pharmaceutical preparation can be in the form of a liquid solution or suspension immediately prior to administration, but may also take another form such as a syrup, cream, ointment, tablet, capsule, powder, gel, matrix, suppository, or the like.
- the pharmaceutical compositions comprising one or more tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) and other agents may be administered using the same or different routes of administration in accordance with any medically acceptable method known in the art.
- compositions comprising one or more tyrosine kinase inhibitors are administered prophylactically, e.g., to prevent T cell exhaustion.
- tyrosine kinase inhibitors e.g., dasatinib, ponatinib
- other agents are administered prophylactically, e.g., to prevent T cell exhaustion.
- prophylactic uses will be of particular value for subjects with a chronic infection or cancer, who are at risk of developing T cell exhaustion.
- the pharmaceutical compositions comprising one or more tyrosine kinase inhibitors are in a sustained-release formulation, or a formulation that is administered using a sustained-release device.
- tyrosine kinase inhibitors e.g., dasatinib, ponatinib
- other agents are in a sustained-release formulation, or a formulation that is administered using a sustained-release device.
- sustained-release devices include, for example, transdermal patches, and miniature implantable pumps that can provide for drug delivery over time in a continuous, steady-state fashion at a variety of doses to achieve a sustained-release effect with a non-sustained-release pharmaceutical composition.
- the invention also provides a method for administering a conjugate comprising a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) as provided herein to a patient suffering from a condition that is responsive to treatment with a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) contained in the conjugate or composition.
- the method comprises administering, via any of the herein described modes, a therapeutically effective amount of the conjugate or drug delivery system, preferably provided as part of a pharmaceutical composition.
- the method of administering may be used to treat any condition that is responsive to treatment with a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib). More specifically, the pharmaceutical compositions herein are effective in treating T cell exhaustion.
- a tyrosine kinase inhibitor e.g., dasatinib, ponatinib.
- tyrosine kinase inhibitor e.g., dasatinib, ponatinib
- the actual dose to be administered will vary depending upon the age, weight, and general condition of the subject as well as the severity of the condition being treated, the judgment of the health care professional, and conjugate being administered.
- Therapeutically effective amounts can be determined by those skilled in the art, and will be adjusted to the particular requirements of each particular case.
- a therapeutically effective amount will range from about 0.50 mg to 5 grams of a tyrosine kinase inhibitor daily, more preferably from about 5 mg to 2 grams daily, even more preferably from about 7 mg to 1.5 grams daily.
- such doses are in the range of 10-600 mg four times a day (QID), 200-500 mg QID, 25-600 mg three times a day (TID), 25-50 mg TID, 50-100 mg TID, 50-200 mg TID, 300-600 mg TID, 200-400 mg TID, 200-600 mg TID, 100 to 700 mg twice daily (BID), 100-600 mg BID, 200-500 mg BID, or 200-300 mg BID.
- the amount of compound administered will depend on the potency of the tyrosine kinase inhibitor and the magnitude or effect desired and the route of administration.
- a purified tyrosine kinase inhibitor (again, preferably provided as part of a pharmaceutical preparation) can be administered alone or in combination with one or more other therapeutic agents, such as other drugs for treating T cell exhaustion (e.g., anti-PD-1 checkpoint inhibitor, such as nivolumab), or other medications used to treat a subject for an infection or disease associated with T cell exhaustion (e.g., antiviral, antibiotic, or anti-cancer drugs); or adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy); or other medications used to treat a particular condition or disease according to a variety of dosing schedules depending on the judgment of the clinician, needs of the patient, and so forth.
- other drugs for treating T cell exhaustion e.g., anti-PD-1 checkpoint inhibitor, such as nivolumab
- dosing schedules include, without limitation, administration five times a day, four times a day, three times a day, twice daily, once daily, three times weekly, twice weekly, once weekly, twice monthly, once monthly, and any combination thereof.
- Preferred compositions are those requiring dosing no more than once a day.
- a tyrosine kinase inhibitor can be administered prior to, concurrent with, or subsequent to other agents or therapies. If provided at the same time as other agents or therapies, one or tyrosine kinase inhibitors can be provided in the same or in a different composition. Thus, one or more tyrosine kinase inhibitors and other agents can be presented to the individual by way of concurrent therapy.
- concurrent therapy is intended administration to a subject such that the therapeutic effect of the combination of the substances is caused in the subject undergoing therapy.
- concurrent therapy may be achieved by administering a dose of a pharmaceutical composition comprising a tyrosine kinase inhibitor and a dose of a pharmaceutical composition comprising at least one other agent, such as another drug for treating T cell exhaustion, which in combination comprise a therapeutically effective dose, according to a particular dosing regimen.
- a pharmaceutical composition comprising a tyrosine kinase inhibitor and a dose of a pharmaceutical composition comprising at least one other agent, such as another drug for treating T cell exhaustion, which in combination comprise a therapeutically effective dose, according to a particular dosing regimen.
- one or more tyrosine kinase inhibitors and one or more other therapeutic agents can be administered in at least one therapeutic dose.
- Administration of the separate pharmaceutical compositions or therapies can be performed simultaneously or at different times (i.e., sequentially, in either order, on the same day, or on different days), as long as the therapeutic effect of the combination of these substances is caused in the subject undergoing therapy.
- kits comprising one or more containers holding compositions comprising at least one tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) and optionally one or more other agents for treating T cell exhaustion.
- Compositions can be in liquid form or can be lyophilized.
- Suitable containers for the compositions include, for example, bottles, vials, syringes, and test tubes.
- Containers can be formed from a variety of materials, including glass or plastic.
- a container may have a sterile access port (for example, the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
- the kit can further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution, or dextrose solution. It can also contain other materials useful to the end-user, including other pharmaceutically acceptable formulating solutions such as buffers, diluents, filters, needles, and syringes or other delivery devices.
- a pharmaceutically-acceptable buffer such as phosphate-buffered saline, Ringer's solution, or dextrose solution.
- the delivery device may be pre-filled with the compositions.
- the kit can also comprise a package insert containing written instructions for methods of using the compositions comprising at least one tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) for treating a subject for T cell exhaustion.
- the package insert can be an unapproved draft package insert or can be a package insert approved by the Food and Drug Administration (FDA) or other regulatory body.
- Example I A Method of Preventing or Reversing T Cell Exhaustion by Inhibiting or Modulating TCR Signaling
- CAR T cells were washed, resuspended in media containing S1, and mixed at a 1:1 ratio with Nalm6 leukemic cells stably expressing surface GD2. Culture supernatants were harvested approximately 24 hours later and cytokine levels were evaluated via ELISA. Similar to GD2.28z CAR that lacks a destabilization domain and therefore have persistent high levels of CAR signaling, cells expressing the GD2.28z.FKBP CAR that experienced continuous drug treatment ( FIG.
- nivolumab (Nivo). CART cells were either treated with continuous S1 (and thus exhibit continuous tonic signaling), continuous S1+nivolumab, or no S1 until the time of the co-culture assay. Interestingly, nivolumab treatment resulted in only modest augmentation of IL-2 secretion at day 10, which was sustained until day 14, suggesting that nivolumab only partially prevented the onset of T cell exhaustion in this system ( FIG. 5 ).
- HA-GD2.28z.FKBP CAR T cells that had experienced continuous S1 treatment were sorted in order to isolate a pure PD-1/TIM-3/LAG-3 exhausted population. “Triple positive” exhausted cells were then re-cultured either with or without S1 to test whether removal of tonic signaling could restore their function. FACS and co-culture assays were conducted 4 days later.
- kinases in the TCR signaling pathway that are also integral to CAR signaling.
- Lck acts to phosphorylate CD3 zeta in response to TCR or CAR ligation.
- Dasatinib a potent receptor tyrosine kinase inhibitor and BCR/ABL antagonist, has also been shown to inhibit T cell activation, proliferation, and cytokine secretion by binding to and inhibiting Lck at low concentrations (Schade et. al, Blood, 2008 and Lee et. al, Leukemia, 2010).
- dasatinib potently inhibits CD19.28z CART cell cytokine secretion in response to tumor antigen on day 14 post-activation ( FIG. 7 ), proving that dasatinib disrupts CAR signaling.
- dasatinib treatment resulted in preservation of T cell memory via maintenance of CD62L expression in a dose-dependent manner ( FIG. 9 .).
- dasatinib treatment reinvigorated exhausted T cells in a functionally significant manner, as dasatinib-treated CAR T cells secreted more IL-2 (and to a lesser extent, IFN ⁇ ) in response to tumor antigen compared to those that never received dasatinib ( FIG. 10 ).
- Chimeric antigen receptors are synthetic receptors that combine an extracellular tumor-targeting domain with intracellular domains that mimic endogenous TCR signaling (e.g., 1-2 costimulatory domains, like CD28 or 4-1BB, and a CD3 zeta domain) (see, e.g., Lim & June. Cell 168, 724-740 (2017)).
- CAR T cells When CAR-expressing T cells encounter antigen-expressing tumor cells, CAR T cells form an immune synapse and initiate downstream signaling through the CAR, resulting in potent T cell activation, degranulation of cytotoxic soluble factors, cytokine release, and proliferation.
- CAR T cell therapy has experienced unprecedented clinical success in many patients with hematological malignancies, there are several key challenges that must be addressed before this therapy can be expanded to other tumor types or offered as first-line therapy.
- CAR toxicity typically manifests in the form of cytokine release syndrome (CRS) or on-target off-tumor activity, both of which have been observed in clinical trials and, in some instances, resulted in patient death (see, e.g., Gust et al. Cancer discovery (2017). doi:10.1158/2159-8290.cd-17-0698; Xu & Tang. Cancer Letters 343, 172-178 (2014); D'Aloia, et al. Cell Death & Disease 9, 282 (2018)).
- CRS cytokine release syndrome
- a second key challenge to improving the efficacy of CAR T cell therapy is the prevention of CAR T cell exhaustion.
- T cell exhaustion results from continuous antigen exposure in the context of chronic viral infection or cancer and is characterized by a hierarchical loss of effector function, sustained co-expression of multiple inhibitory receptors (ex., PD-1, TIM-3, LAG-3), attenuated proliferative capacity, and increase apoptosis (see, e.g., Wherry & Kurachi. Nature Reviews Immunology 15, nri3862 (2015)).
- PD-1 PD-1, TIM-3, LAG-3
- LAG-3 multiple inhibitory receptors
- There is strong evidence for T cell exhaustion in CART cell therapy Nearly all CD19.28z CART cells administered disappear by day 60 post-infusion (see, e.g., Lee et al.
- CD19.BBz CART cells which are thought to be more resistant to T cell exhaustion, also exhibit features of exhaustion and are undetectable in approximately 30% of patients who receive this therapy, consequently increasing the risk of CD19 positive relapse (see, e.g., Turtle et al. Journal of Clinical Investigation 126, 2123-2138 (2016); Maude et al. The New England Journal of Medicine 371, 1507-1517 (2014)).
- T cells expressing the CD19-targeting CAR were incubated with various concentrations of dasatinib and ponatinib for at least 24 hours.
- CAR T cells were next co-cultured with antigen-bearing tumor cells for 6 hours in the presence or absence of dasatinib/ponatinib, and subsequently assessed CAR T cell activation and degranulation via CD69 and CD107a co-expression. Nearly 80% of control CART cells were CD69+/CD107a+ upon co-culture with tumor ( FIG. 11 a ).
- Control HA-GD2.28z CART cells exhibited robust single marker expression and co-expression of multiple canonical exhaustion markers ( FIG. 15 ). Conversely, expansion in dasatinib reduced both the frequency of exhaustion-marker co-expressing cells as well as the extent to which these exhaustion markers were expressed in a dose-dependent manner ( FIG. 15 ).
- CART cell expansion in the presence of dasatinib also augmented T cell memory formation, as a nearly 6-fold increase in the frequency of central-memory-like T cells (CD45RA low, CCR7 high) and a greater-than 2-fold reduction in the frequency of effector-memory-like T cells (CD45RA low, CCR7 low) was observed compared to exhausted CAR T cells cultured in the absence of dasatinib.
- Tonically signaling CAR T cells cultured in the absence of dasatinib or ponatinib secreted low levels of cytokine in response to tumor ( FIG. 17 ) and exhibited impaired cytotoxicity ( FIG. 18 ), indicating that these cells were functionally exhausted.
- expansion of CAR T cells in the presence of dasatinib or ponatinib dose-dependently augmented CAR T cell cytokine secretion ( FIG. 17 ) and also allowed for a more potent cytotoxic response ( FIG. 18 ), confirming that the mitigation of tonic signaling during CAR T cell expansion with these drugs confers profound functional benefits.
- CAR T cells were expanded with or without 1 uM dasatinib and subsequently infused into NSG mice engrafted with antigen-bearing tumor.
- both GD2.BBz and HA-GD2.28z CAR T cells grown in the absence of dasatinib failed to control tumor growth ( FIGS. 19 and 20 , respectively).
- CAR T cells expanded in dasatinib allowed for a near complete and lasting eradication of the tumor ( FIGS. 19 and 20 ).
- the same effect was observed in a GD2-overexpressing NALM6 leukemia model in which the tumor burden was more established at the time of CART cell infusion ( FIG. 21 ).
- CAR T cells were infused into mice that had been engrafted with antigen-bearing tumor.
- blood samples were taken from the mice and the number of circulating CAR T cells was assessed via FACS counting beads.
- Tonically signaling HA-GD2.28z CAR T cells expanded in the absence of dasatinib did not expand and/or persist at levels greater than mice infused with mock untransduced T cells ( FIG. 22 ).
- CAR T cells were infused into mice that were engrafted with antigen-bearing tumor and subsequently dosed with dasatinib for 3 consecutive days. The mice were then sacrificed and CAR T cell frequency and phenotype assessed in both the blood and the spleen.
- the dasatinib-treated mouse exhibited a higher frequency of CAR T cells in both tissues ( FIG. 22 a, c ) compared to the vehicle-treated mouse, indicating that in vivo dasatinib treatment induced in situ proliferation or persistence.
- CAR T cells that were recovered from the dasatinib-treated mouse exhibited reduced expression of exhaustion markers PD-1 and LAG-3, reduced expression of CD69 (i.e. lower activation state), and higher expression of the memory marker CD62L ( FIG. 22 b, d ) compared to the vehicle-treated mouse, all of which are consistent with the phenotypic changes observed upon in vitro treatment with dasatinib ( FIG. 15, 16 ).
- dasatinib mitigates CAR T cell exhaustion phenotype and improves memory formation, and indicates that in vivo dasatinib dosing provides a functional benefit in vivo.
- CAR T cells were infused into mice that exhibited high tumor burden.
- the mice were dosed with dasatinib or vehicle for 3 consecutive days, then were not treated for a period of 3 additional days.
- tumor burden was assessed and a profound decrease in tumor size in the dasatinib-treated mouse was observed ( FIG. 22 e ).
- the tumor burden in vehicle-treated mouse continued to increase, indicating that the augmentation in anti-tumor response was specific to dasatinib treatment.
- dasatinib and ponatinib have the potential to address several important challenges currently facing the field of adoptive T cell therapies (e.g., CART cell therapies).
- CART cell therapies e.g., CART cell therapies.
- these drugs were shown potently inhibit CAR signaling, which provides a method to regulate CAR activity and thus mitigate CAR T cell toxicity while preserving the option to continue therapy once the toxicity has resolved, as the inhibitory effect of dasatinib and ponatinib on CAR T cell function is reversible.
- Second, expansion of CAR T cells in the presence of dasatinib or ponatinib was shown to prevent CAR tonic signaling and in turn enhance the functional capacity of CAR T cells.
- providing short periods of CAR T cell “rest” in vivo via iterative drug dosing was shown to be one method by which CAR T cell exhaustion could be prevented or reversed and/or memory could be induced.
- Example II describes the materials and methods for Example II.
- NALM6-GL acute lymphoblastic leukemia line, stably transfected with GFP and luciferase
- NALM6-GL-GD2 stably transfected to overexpress GD2 synthetase cell lines
- RPMI-1640 293T and 143B cell lines were cultured in DMEM (Life Technologies).
- T cells Primary human T cells were obtained from healthy donor buffy coats using a Pan T cell negative selection kit (Miltenyi Biotec). Donor T cells were then aliquoted and stored in Cryostor (StemCell Technologies) in liquid nitrogen. T cells were cultured in AimV (Gibco, Life Technologies) supplemented with 5% heat-inactivated FBS, 10 mM HEPES, 1% glutamax (Gibco, Life Technologies), and 100 u/uL recombinant human IL-2 (Peprotech). Dasatinib (Sigma Aldrich and Adooq Biosciences) or ponatinib (SelleckChem) were cultured at 1 uM unless otherwise specified.
- T cells Upon thawing, T cells were activated at a 3:1 bead:cell ratio using anti-CD3/anti-CD28-coated magnetic beads (Dynabeads, Thermo Fisher) at a concentration of 1 ⁇ 10 6 cells/mL.
- T cells On days 2 and 3 post-activation, T cells were transduced with retrovirus encoding the CAR. Briefly, retrovirus was first spun onto retronectin-coated plates at 3000 rpm for 2 hours, after which T cells were transferred to the plates. On day 4 post-activation, magnetic beads were removed from culture, and T cells were cultured at 0.5 ⁇ 10 6 cells/mL every day thereafter. Media supplemented with IL-2 and drug was changed every two days. Transduction efficiencies were routinely 70-90% for all CARs.
- T cell phenotype was evaluated via: CD4 (OKT4, Biolegend), CD8 (SK1, Biolegend), PD-1 (eBioJ105, eBioscience), TIM-3 (F38-2E2, Biolegend), LAG-3 (3DS223H, eBioscience), CD45RA (L48, BD Biosciences), CCR7 (150503, BD Biosciences), CD62L (DREG-56, BD Biosciences), CD69 (FN50, Biolegend), and CD107a (H4A3, eBioscience).
- CD107a For co-culture assays in which CD107a was assessed, tumor cells and CAR T cells were co-cultured in the presence of 1:1000 monensin (eBioscience) and anti-CD107a for at least 6 hours. All FACS plots displaying CART cell phenotype data were pre-gated on CAR+ cells.
- whole T cell populations were used for analysis.
- 50,000 NALM6-GL-GD2 tumor cells were co-cultured with T cells at a 1:1 E:T ratio in 200 uL of complete AimV medium without IL-2 supplementation in each well of a 96-well plate. After 24 hours, supernatants were removed and stored at ⁇ 20 C. IL-2 and IFN ⁇ secretion was assessed via ELISA (Biolegend).
- CAR′ cells were removed from culture, pelleted, and resuspended in 100 uL of RITA lysis buffer (10 mM Tris-Cl pH 8.0, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl) supplemented with phosphatase and protease inhibitors (Thermo Fisher), After incubating for 30 minutes at 4 C, supernatants were cleared by centrifugation at 14,000 RPM for 20 minutes at 4 C. Protein concentration in the cleared lysates was measured by a colorimetric reaction (BioRad).
- RITA lysis buffer 10 mM Tris-Cl pH 8.0, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl
- phosphatase and protease inhibitors Thermo Fisher
- CD3-zeta Cell signaling
- pY142-CD3-zeta Cell Signaling
- p44/42 MAPK Erk1/2, Cell Signaling
- p-p44/42 MAPK p-ERK1/2, Cell Signaling
- pSer473-Akt D9E, Cell Signaling
- pan Akt 40D4, Cell Signaling
- LI-COR The Odyssey (LI-COR) imaging system. LI-COR buffers, and LI-COR secondary antibodies (Goat Anti-Mouse IgG Antibody-800CW-Conjugated and Goat Anti-Rabbit IgG Antibody-680LT-Conjugated) were used for protein detection.
- CAR T cells were incubated in 5 ug/mL anti-idiotype (clone 1A7) plus 5 ug/mL goat anti-mouse Fab secondary (Jackson Immunoresearch) or secondary alone for 5 minutes at 37 C. Cells were then quenched in ice cold PBS, pelleted at 4 C for 5 minutes, then lysed for western blot analysis.
- mice were engrafted with 1 ⁇ 10 6 NALM6-GL-GD2 leukemia cells via intravenous injection. At day 4 post-engraftment, 2 ⁇ 10 6 HA-GD2.28z CAR+ T cells were infused intravenously.
- NALM6-GL-GD2 tumor burden was evaluated using the Xenogen IVIS Lumina (Caliper Life Sciences). Mice were first injected intraperitoneally with 3 mg D-luciferin (Caliper Life Sciences) and then imaged 4 minutes later with an exposure time of 30 seconds, or, in cases where 30 seconds resulted in signal saturation, “auto” exposure was selected. Luminescence images were analyzed using Living Image software (Caliper Life Sciences).
- mice 6-8 week old NSG mice were engrafted with 0.5 ⁇ 10 6 143 B osteosarcoma cells intramuscularly. On day 3 post-engraftment, 10 ⁇ 10 6 GD2.BBz or HA-GD2.28z were infused intravenously. Osteosarcoma burden was quantified via two-dimensional leg area measurements.
- mice treated with dasatinib (Adooq Biosciences) were injected intraperitoneally at a concentration of 50 mg/kg in water+10% Kolliphor HS 15 (Sigma Aldrich). Mice treated with vehicle were injected with an equivalent volume of water+10% Kolliphor HS 15.
- Each CAR includes a signal peptide, single chain variable fragment (scFv), extracellular hinge region, transmembrane domain, intracellular co-stimulatory domain, and intracellular CD3 zeta domain.
- scFv single chain variable fragment
- the nucleic acid and amino acid sequence for CD19.28z (FMC63 scFv) is provided at FIG. 23 .
- CD19.BBz FMC63 scFv
- FIG. 24 The nucleic acid and amino acid sequence for CD19.BBz (FMC63 scFv) is provided at FIG. 24 .
- the nucleic acid and amino acid sequence for GD2.BBz (14G2a scFv) is provided at FIG. 25 .
- the nucleic acid and amino acid sequence for HA-GD2.28z (High affinity 14G2a scFv) is provided at FIG. 26 .
Abstract
Description
- This application claims the benefit of U.S. provisional application Ser. No. 62/479,930, filed Mar. 31, 2017, which is incorporated herein by reference in its entirety.
- Provided herein are compositions and methods for preventing or reversing T cell exhaustion. In particular, the present invention relates to methods of preventing or reversing T cell exhaustion by exposing T cells experiencing T cell exhaustion to particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib), or by expanding genetically engineered T cells in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib).
- T cells are immune cells that become activated via T cell receptor (TCR) signaling following engagement with antigen. Physiologic activation through the T cell receptor renders T cells capable of mediating potent antitumor or anti-infective effects. During resolution of an acute inflammatory response, a subset of activated effector T cells differentiate into long-lived memory cells. By contrast, in patients with chronic infections or cancer, T cells not infrequently undergo pathologic differentiation toward a state of dysfunction, which has been termed T cell exhaustion. T cell exhaustion is characterized by marked changes in metabolic function, transcriptional programming, loss of effector function (e.g., cytokine secretion, killing capacity), and co-expression of multiple surface inhibitory receptors. The root cause of T cell exhaustion is persistent antigen exposure leading to continuous TCR signaling. Prevention or reversal of T cell exhaustion has been long sought as a means to enhance T cell effectiveness in patients with cancer or chronic infections.
- The present invention addresses this urgent need.
- Immune cells respond to the presence of foreign antigens with a wide range of responses, including the secretion of preformed and newly formed mediators, phagocytosis of particles, endocytosis, cytotoxicity against target cells, as well as cell proliferation and/or differentiation. T cells are a subgroup of cells which together with other immune cell types (e.g., polymorphonuclear, eosinophils, basophils, mast cells, B cells, and NK cells), constitute the cellular component of the immune system (see, e.g., U.S. Pat. No. 6,057,294; US Pat. Appl. 20050070478). Under physiological conditions T cells function in immune surveillance and in the elimination of foreign antigen. However, under pathological conditions there is compelling evidence that T cells play a major role in the causation and propagation of disease. In these disorders, breakdown of T cell immunological tolerance, either central or peripheral is a fundamental process in the causation of autoimmune disease.
- It is well established that T cell receptor (TCR) engagement and costimulatory signaling provide the critical signals that regulate T cell activation, proliferation and cytolytic functions. T cells respond to antigen via a polypeptide complex composed of the ligand-binding T cell receptor (TCR) disulfide-linked α and β subunits (or γ and δ subunits in γδ T cells) that have single transmembrane (TM) spans per subunit and small intracellular tails and associate non-covalently with hetero- (CD3γε and CD3δε) and homodimeric (ζζ) signaling subunits (see, e.g., Cambier J. C. Curr Opin Immunol 1992; 4:257-64). The CD3ε, δ, and γ chains have single Ig-family extracellular domains, single presumably α-helical TM spans, and intrinsically disordered intracellular domains of 40-60 residues, whereas each subunit has a small extracellular region (9 residues) carrying the intersubunit disulfide bond, a single presumably α-helical TM span per subunit, and a large, intrinsically disordered cytoplasmic domain of approximately 110 residues. An understanding of the process of TCR-mediated TM signal transduction and subsequent T cell activation, leading to T cell proliferation and differentiation, is therefore pivotal to both health and disease. Disturbance in TCR signaling can lead to inflammatory and other T cell-related disorders.
- T cells expressing chimeric antigen receptors (CARs) at high levels undergo tonic, antigen independent signaling due to receptor clustering. Such T cells function poorly as a result of T cell exhaustion, as evidenced by high levels of PD-1, TIM-3, LAG-3, diminished antigen induced cytokine production, and excessive programmed cell death. Tonic signaling can be prevented by transiently decreasing CAR associated TCR signaling proteins (e.g., TCR zeta) to levels below the threshold required for tonic signaling.
- Experiments conducted during the course of developing embodiments for the present invention demonstrated that treatment with a particular tyrosine kinase inhibitor that inhibits T cell receptor signaling (e.g., a Lck tyrosine kinase inhibitor (e.g., dasatinib)) (e.g., a Src family tyrosine kinase inhibitor) reduced expression of the T cell exhaustion markers and improved formation of T cell memory. Accordingly, the present invention relates to methods of preventing or reversing T cell exhaustion by transiently inhibiting T cell receptor (TCR) signaling to restore T cell function with particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib).
- Additional experiments determined that CAR T cells co-cultured with tumor cells in the presence of dasatinib or ponatinib exhibit attenuated activation and degranulation, fail to secrete cytokine, and display attenuated killing in response to tumor antigen.
- Additional experiments determined that dasatinib potently inhibits the phosphorylation of CAR CD3z as well as distal signaling proteins after CAR crosslinking.
- Additional experiments determined that tonically signaling CAR T cells expanded in the presence of dasatinib exhibit a reduction in canonical exhaustion marker expression in a dose-dependent manner, retain the capacity to form memory, display augmented cytokine secretion in response to tumor antigen, and display augmented cytotoxicity.
- Additional experiments determined that in vivo dasatinib treatment suppresses exhaustion marker expression, augments memory formation, and facilitates cell survival/proliferation.
- Accordingly, provided herein are compositions and methods for preventing or reversing T cell exhaustion. In particular, the present invention relates to methods of preventing or reversing T cell exhaustion by exposing T cells experiencing T cell exhaustion to particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib), or by expanding genetically engineered T cells in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib).
- In certain embodiments, the present invention provides methods for treating a subject to mitigate T cell exhaustion, the method comprising administering to the subject a therapeutically effective amount of a tyrosine kinase inhibitor. Such embodiments are not limited to a particular tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is capable of inhibiting TCR signaling and/or CAR signaling. In some embodiments, the tyrosine kinase inhibitor is a Lck kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is a Fyn kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is a Src family tyrosine kinase inhibitor. In some embodiments, tyrosine kinase inhibitor is dasatinib or ponatinib. In some embodiments, the treatment is prophylactic.
- Such methods are not limited to a particular manner of treating the subject for T cell exhaustion. In some embodiments, the treatment increases secretion of IL-2 by T cells in the subject. In some embodiments, the treatment decreases apoptosis of T cells in the subject. In some embodiments, the treatment decreases expression of at least one T cell exhaustion marker selected from the group consisting of PD-1, TIM-3, and LAG-3. In some embodiments, the treatment increases expression of CD62L or CCR7.
- Such methods are not limited to particular manner of administration. In some embodiments, multiple cycles of treatment are administered to the subject. In some embodiments, the tyrosine kinase inhibitor is administered intermittently. In some embodiments, the tyrosine kinase inhibitor is administered for a period of time sufficient to restore at least partial T cell function then discontinued. In some embodiments, the tyrosine kinase inhibitor is administered orally.
- Such methods are not limited to a particular type or kind of subject. In some embodiments, the subject is a human. In some embodiments, the subject has a chronic infection or cancer.
- In certain embodiments, the present invention provides for treating an immune system related condition or disease in a subject comprising administering to the subject genetically engineered T cells and a therapeutically effective amount of a tyrosine kinase inhibitor. Such embodiments are not limited to a particular tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is capable of inhibiting TCR signaling and/or CAR signaling. In some embodiments, the tyrosine kinase inhibitor is a Lck kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is a Fyn kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is a Src family tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is dasatinib or ponatinib. In some embodiments, the treatment is prophylactic. In some embodiments, the tyrosine kinase inhibitor and the genetically engineered T cells are administered simultaneously and/or at different time points.
- Such methods are not limited to a specific type or kind of genetically engineered T cells. In some embodiments, the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.
- Such methods are not limited to treating a specific immune system related condition or disease. In some embodiments, the immune system related condition or disease is selected from cancer or an autoimmune disease or condition.
- In certain embodiments, the present invention provides methods for preventing and/or reversing toxicity related to genetically engineered T cell administered to a subject, comprising administering to the subject a therapeutically effective amount of a tyrosine kinase inhibitor. Such embodiments are not limited to a particular tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is capable of inhibiting TCR signaling and/or CAR signaling. In some embodiments, the tyrosine kinase inhibitor is a Lck kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is a Fyn kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is a Src family tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is dasatinib or ponatinib.
- Such methods are not limited to a specific type or kind of genetically engineered T cells. In some embodiments, the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.
- Such methods are not limited to a particular type or kind of adoptive T cell therapy. In some embodiments, the adoptive T cell therapy is a CAR T-cell therapy. In some embodiments, the adoptive T cell therapy is a transduced T-cell therapy. In some embodiments, the adoptive T cell therapy is a tumor infiltrating lymphocyte (TIL) therapy.
- Such methods are not limited to a particular type or kind of toxicity related to genetically engineered T cell administered to a subject. In some embodiments, the toxicity related to genetically engineered T cell administered to a subject is cytokine release syndrome. In some embodiments, the toxicity related to genetically engineered T cell administered to a subject is on-target off tumor toxicity or off-target off-tumor toxicity.
- In certain embodiments, the present invention provides compositions comprising a genetically engineered T cell population, wherein the genetically engineered T cell population was expanded in the presence of tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is capable of inhibiting TCR signaling and/or CAR signaling inhibitor. In some embodiments, the tyrosine kinase inhibitor dasatinib or ponatinib.
- In certain embodiments, the present invention provides methods of generating a population of genetically engineered T cells resistant to T cell exhaustion, comprising expanding a population of genetically engineered T cells in the presence of a tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is capable of inhibiting TCR signaling and/or CAR signaling inhibitor. In some embodiments, the tyrosine kinase inhibitor is dasatinib or ponatinib. Such methods are not limited to a specific type or kind of genetically engineered T cells. In some embodiments, the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR. Such methods are not limited to a specific expanding technique as such techniques are well known in the art.
- In certain embodiments, the present invention provides methods of treating an immune system related condition or disease in a subject undergoing an adoptive T cell therapy, comprising administering to the subject a genetically engineered T cell population that were expanded in the presence of a tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is capable of inhibiting TCR signaling inhibitor and/or CAR signaling. In some embodiments, the tyrosine kinase inhibitor is a Lck kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is a Fyn kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is a Src family tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is dasatinib or ponatinib. In some embodiments, the immune system related condition or disease is selected from cancer or an autoimmune disease or condition.
- Such methods are not limited to a specific type or kind of genetically engineered T cells. In some embodiments, the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.
- Such methods are not limited to a particular type or kind of adoptive T cell therapy. In some embodiments, the adoptive T cell therapy is a CAR T-cell therapy. In some embodiments, the adoptive T cell therapy is a transduced T-cell therapy. In some embodiments, the adoptive T cell therapy is a tumor infiltrating lymphocyte (TIL) therapy.
- The present invention contemplates that exposure of animals (e.g., humans) suffering from cancer (e.g., and/or cancer related disorders) to adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy) with genetically engineered T cell populations and compositions comprising particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) will inhibit the growth of cancer cells or supporting cells outright and/or render such cells as a population more susceptible to the cell death-inducing activity of cancer therapeutic drugs or radiation therapies. In such embodiments, the methods result in improved therapy outcome as such particular tyrosine kinase inhibitors are capable of 1) modulating TCR signaling within the genetically engineered T cell population (e.g., decreasing expression of one or more of PD-1, TIM-3, and LAG-3; increasing expression of memory markers (e.g., CD62L or CCR7); increasing secretion of IL-2 and other cytokines), and 2) preventing and/or reversing T cell exhaustion within the genetically engineered T cell population. Thus, the present invention provides methods for treating cancer (e.g., and/or cancer related disorders) with adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy) in a subject comprising administering to the subject (e.g., simultaneously and/or at different time points) genetically engineered T cells, particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib), and additional cancer therapeutic drugs or radiation therapies.
- The present invention contemplates that exposure of animals (e.g., humans) suffering from cancer (e.g., and/or cancer related disorders) to adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy) with genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) will inhibit the growth of cancer cells or supporting cells outright and/or render such cells as a population more susceptible to the cell death-inducing activity of cancer therapeutic drugs or radiation therapies. In such embodiments, the methods result in improved therapy outcome as such genetically engineered T cell populations are resistant and/or less prone to T cell exhaustion. Thus, the present invention provides methods for treating cancer (e.g., and/or cancer related disorders) with adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy) in a subject comprising administering to the subject (e.g., simultaneously and/or at different time points) genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) and additional cancer therapeutic drugs or radiation therapies.
- The present invention contemplates that such methods (e.g., adoptive T cell therapies with genetically engineered T cell populations and compositions comprising particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib)) (e.g., adoptive T cell therapies with genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib)) satisfy an unmet need for the treatment of multiple cancer types, either when administered as monotherapy or when administered in a temporal relationship with additional agent(s), such as other cell death-inducing or cell cycle disrupting cancer therapeutic drugs or radiation therapies (combination therapies), so as to render a greater proportion of the cancer cells or supportive cells susceptible to executing the apoptosis program compared to the corresponding proportion of cells in an animal treated only with the cancer therapeutic drug or radiation therapy alone.
- In certain embodiments of the invention, combination treatment of animals with such methods (e.g., adoptive T cell therapies with genetically engineered T cell populations and compositions comprising particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib)) (e.g., adoptive T cell therapies with genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib)) produce a greater tumor response and clinical benefit in such animals compared to those treated with the anticancer drugs/radiation alone. Since the doses for all approved anticancer drugs and radiation treatments are known, the present invention contemplates the various combinations of them with such methods.
- A non-limiting exemplary list of cancer (e.g., and/or cancer related disorders) includes, but is not limited to, pancreatic cancer, breast cancer, prostate cancer, lymphoma, skin cancer, colon cancer, melanoma, malignant melanoma, ovarian cancer, brain cancer, primary brain carcinoma, head and neck cancer, glioma, glioblastoma, liver cancer, bladder cancer, non-small cell lung cancer, head or neck carcinoma, breast carcinoma, ovarian carcinoma, lung carcinoma, small-cell lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, bladder carcinoma, pancreatic carcinoma, stomach carcinoma, colon carcinoma, prostatic carcinoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, myeloma, multiple myeloma, adrenal carcinoma, renal cell carcinoma, endometrial carcinoma, adrenal cortex carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, choriocarcinoma, mycosis fungoides, malignant hypercalcemia, cervical hyperplasia, leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic granulocytic leukemia, acute granulocytic leukemia, hairy cell leukemia, neuroblastoma, rhabdomyosarcoma, Kaposi's sarcoma, polycythemia vera, essential thrombocytosis, Hodgkin's disease, non-Hodgkin's lymphoma, soft-tissue sarcoma, osteogenic sarcoma, primary macroglobulinemia, and retinoblastoma, and the like, T and B cell mediated autoimmune diseases; inflammatory diseases; infections; hyperproliferative diseases; AIDS; degenerative conditions, vascular diseases, and the like. In some embodiments, the cancer cells being treated are metastatic. In other embodiments, the cancer cells being treated are resistant to anticancer agents.
-
FIG. 1 : Characterization of the GD2.28z.FKBP CAR. T cells were transduced with lentivirus encoding the GD2.28z.FKBP CAR onday 1 after activation and subsequently cultured with various concentrations of shield-1 in the growth medium. Onday 7, CAR expression was quantified via FACS. -
FIG. 2 : Removal of S1 from culture medium results in reversal of T cell exhaustion marker surface expression. -
FIG. 3 : Removal of S1 from culture medium results in maintenance of CD62L expression and prevention of apoptosis. -
FIG. 4 : Removal of S1 from culture medium results in reversal of function T cell exhaustion. -
FIG. 5 : Removal of surface CAR results in more effective prevention of T cell exhaustion compared PD-1/PDL-1 blockade. -
FIG. 6 : Removal of surface CAR rescues exhaustion in PD-1/TIM-3/LAG-3 triple positive CAR T cells after only 4 days. -
FIG. 7 : Dasatinib inhibits cytokine secretion of CAR T cells in response to tumor antigen. -
FIG. 8 : Dasatinib reverses exhaustion marker expression and co-expression. -
FIG. 9 : Dasatinib treatment results in maintenance of CD62L expression. -
FIG. 10 : Dasatinib Treatment results in augmented IL-2 and IFNγ secretion in response to tumor antigen. -
FIG. 11 : CAR T cells co-cultured with tumor cells in the presence of dasatinib or ponatinib exhibit attenuated activation and degranulation. As shown, CD19.28z CAR T cells were cultured in the presence or absence of various concentrations of dasatinib or ponatinib for at least 48 hours. CAR T cells were then co-cultured with CD19-bearing Nalm6 tumor cells for 6 hours. CD69 and CD107a surface expression was subsequently assessed via FACS. Plots display cells gated on the CD8+ CAR+ population. Such results demonstrate that 80% of CD19.28z CART cells become activated (surface CD69 is a surrogate for activation) and degranulate (surface CD107a is a surrogate for degranulation) in response to tumor. However, dasatinib and ponatinib dose-dependently inhibit CAR T cells' ability to respond to tumor in this manner. -
FIG. 12 : CAR T cells co-cultured with tumor cells in the presence of dasatinib or ponatinib fail to secrete cytokine. As shown, high affinity GD2.28z (HA-GD2.28z) CAR T cells were co-cultured with GD2-overexpressing nalm6 for 24 hours in the presence of absence of various concentrations of dasatinib or ponatinib. Supernatant was then collected and analyzed for IL-2 and IFNγ via ELISA. These results demonstrate that using the HA-GD2.28z CAR, dasatinib and ponatinib inhibit CART cell secretion of IL-2 and IFNγ in response to tumor. -
FIG. 13 : CAR T cells cultured in the presence of dasatinib display attenuated killing in response to tumor antigen. An incucyte assay was conducted in which CD19.BBz CAR T cells were co-cultured with nalm6 tumor cells expressing a GFP reporter for 72 hours in the presence of 1 uM dasatinib or vehicle (DMSO). Tumor GFP fluorescence was measured over time. GFP values were normalized to the fluorescence intensity at the first time point. These results demonstrate that dasatinib blunts the ability of the CD19.28z CAR to kill tumor cells.FIGS. 11, 12 and 13 demonstrate that dasatinib or ponatinib could serve as a rapid and reversible safety “OFF” switch for CAR T cells that are having deleterious effects in a given patient. -
FIG. 14 : Dasatinib potently inhibits the phosphorylation of CAR CD3z as well as distal signaling proteins after CAR crosslinking. 2E6 HA-GD2.28z CAR T cells cultured in 1 uM dasatinib or vehicle were removed from culture onday 10 post-activation. Idiotype primary antibody and a crosslinking secondary antibody were then added to the cells at 5 ug/mL to initiate signaling through the CAR. Shown here, dasatinib potently inhibits crosslinking-induced phosphorylation of the CD3z domain on the CAR, as well as phosphorylation of distal signaling kinases Akt and ERK1/2. This is a representative blot of n=3 independent experiments. -
FIG. 15 : Tonically signaling CART cells expanded in the presence of dasatinib exhibit a reduction in canonical exhaustion marker expression in a dose-dependent manner. HA-GD2.28z CART cells were expanded in the presence of various concentrations of dasatinib or vehicle (DMSO). Onday 14 post-activation, cells were removed from cultured, stained, and their exhaustion phenotype was analyzed via FACS. Representative plots from 3 independent experiments.FIG. 15A : CAR+ T cell canonical exhaustion marker expression. -
FIG. 15B : CAR+ CD4+ (left) or CAR+ CD8+ (right) exhaustion marker co-expression. These results demonstrate that the HA-GD2.28z CAR tonically signals in the absence of antigen, which ultimately induces T cells exhaustion, as defined by expression of multiple inhibitory receptors, lack of memory formation, and decreased effector function.FIG. 14 demonstrates that expanding HA-GD2.28z CAR T cells in the presence of dasatinib dose-dependently attenuates exhaustion marker single expression (a) or co-expression (b). -
FIG. 16 : Tonically signaling CAR T cells expanded in the presence of dasatinib retain the capacity to form memory. CD19.28z or HA-GD2.28z were expanded in the presence or absence of 1 uM dasatinib or vehicle (DMSO). OnDay 14 post-activation, cells were removed from cultured for FACS analysis. This representative plot shows CAR+ T cells. The red box highlights the CD45RA low, CCR7 high population, which corresponds to central memory-like T cells. These results demonstrate expanding tonically signaling HA-GD2.28z CAR T cells in dasatinib also augments memory formation, here demonstrated by a marked increase in the CD45RA low, CCR7 high population, which corresponds to a central memory-like phenotype. -
FIG. 17 : Tonically signaling CAR T cells expanded in the presence of dasatinib display augmented cytokine secretion in response to tumor antigen. HA-GD2.28z CAR T cells were expanded in the presence or absence of various concentrations of dasatinib or ponatinib. Drug was removed from the T cells 24 hours prior to co-culture with GD2-overexpressing nalm6 tumor cells in order to allow the T cells to regain the ability to signal in response to tumor. After 24 hours, supernatants were collected and IL-2 and IFNγ secretion was assessed via ELISA.FIGS. 11, 12, 13, 15 and 16 demonstrate that dasatinib and ponatinib can inhibit CART cell signaling and function.FIG. 17 shows that expansion of tonically signaling HA-GD2.28z CART cells in the presence of these drugs followed by remove of the drugs prior to co-culturing with tumor cells results in augmentation of IL-2 and IFNγ. -
FIG. 18 : Tonically signaling CART cells expanded in the presence of dasatinib display augmented cytotoxicity. HA-GD2.28z CAR T cells were expanded in the presence or absence of dasatinib or vehicle (DMSO) for 96 hours. Onday 14 post-activation, dasatinib was removed from the T cells 24 hours prior to an incucyte assay in which T cells were co-cultured at a 1:8 E:T ratio with GD2-overexpressing nalm6 tumor. Tumor GFP fluorescence was measured over time. GFP values were normalized to the fluorescence intensity at the first time point. These results demonstrate that inhibiting tonical signaling of HA-GD2.28z CAR T cells by including dasatinib in the culture medium during expansion followed by removal of dasatinib prior to co-culture rescues the ability of these CAR T cells to kill tumor. -
FIG. 19 : GD2-overexpressing Nalm6 in the presence and absence of dasatinib. 0.5E6 143B tumor cells were engrafted intramuscularly in the legs of mice. Onday 3 post-engraftment, 10E6 GD2.BBz CART cells expanded in the presence of dasatinib or vehicle (DMSO) were infused into mice intravenously. The left plot displays the mean leg area+/−SEM (n=5 mice).FIGS. 19 and 20 recapitulate the findings fromFIGS. 14, 15, 16 and 17 in an in vivo setting. Culturing different types of CARs (GD2.BBz, HA-GD2.28z) in dasatinib and then infusing them in vivo augments their anti-tumor function. -
FIG. 20A : 0.5E6 143B tumor cells were engrafted intramuscularly in the legs of mice. Onday 3 post-engraftment, 10E6 HA-GD2.28z CAR T cells expanded in the presence of dasatinib or vehicle (DMSO) were infused into mice intravenously. The top plot displays the mean leg area+/−SEM (n=5 mice).FIGS. 19 and 20 recapitulate the findings fromFIGS. 14, 15, 16 and 17 in an in vivo setting. Culturing different types of CARs (GD2.BBz, HA-GD2.28z) in dasatinib and then infusing them in vivo augments their anti-tumor function. -
FIG. 20B : 1E6 GD2-overexpressing nalm6 tumor cells were engrafted intravenously in mice. Onday 3 post-engraftment, 2E6 CAR+ HA-GD2.28z CAR T cells expanded in the presence of dasatinib or vehicle (DMSO) were infused into mice intravenously. The top plot displays the mean tumor luminescence+/−SEM (n=5 mice).FIGS. 19 and 20 recapitulate the findings fromFIGS. 14, 15, 16 and 17 in an in vivo setting. Culturing different types of CARs (GD2.BBz, HA-GD2.28z) in dasatinib and then infusing them in vivo augments their anti-tumor function. -
FIG. 21 : 1E6 GD2-overexpressing nalm6 tumor cells were engrafted intravenously in mice. Onday 3 post-engraftment, 2E6 HA-GD2.28z CAR T cells expanded in the presence of dasatinib or vehicle (DMSO) were infused into mice intravenously. On day 17 post-engraftment, blood samples were taken from each mouse and mixed with counting beads. FACS analysis was performed, and the number of CD4+ and CD8+ cells for each mouse was calculated. This plot displays the mean CD4+ or CD8+ cells per mouse+/−SEM (n=5 mice).FIG. 21 demonstrates one of the mechanisms by which dasatinib augments function. After infusing dasatinib-treated CAR T cells into mice, blood samples were taken and the number of circulating CAR T cells analyzed, a typical readout for in vivo CAR T cell proliferation in response to tumor. The vehicle HA-GD2.28z CAR T cells did not exhibit significantly more in vivo proliferation than mock T cells, as these cells were likely exhausted when they were initially infused into the mice. However, CAR T cells that were expanded in dasatinib retained their anti-tumor function and thus proliferated robustly in vivo. -
FIG. 22A ,B,C,D,E: In vivo dasatinib treatment suppresses exhaustion marker expression, augments memory formation, and facilitates cell survival/proliferation. Mice were engrafted with 1E6 GD2-overexpressing nalm6 tumor cells via intravenous injection. Onday 4 post-engraftment, 2E6 HA-GD2.28z CAR T cells were infused into mice intravenously. Mice were dosed with 50 mg/kg dasatinib via intraperitoneal injection on days 21-23 post-tumor engraftment. 5 hours after dasatinib dosing onday 23, 1 mouse receiving vehicle and 1 mouse receiving dasatinib were sacrificed, and spleens/blood were harvested, surface stained, and phenotyped via FACS. A and C) CAR+ T cells constituted a higher percentage of total circulating cells (A) or total splenic cells (C) in the mouse treated with dasatinib versus the vehicle control. B and D) In contrast to mice treated with vehicle (red), circulating or splenic CD8+ CAR+ T cells in dasatinib-treated mice (blue) exhibited a phenotype consistent with a non-activated or resting T cell, indicating that dasatinib suppressed CAR T cell activation and induced memory formation (i.e., higher CD62L expression) in vivo. E) On days 27-29 post-tumor engraftment, 1 mouse received 50 mg/kg dasatinib each day and a different mouse received vehicle control. On days 30-32, mice were untreated. On day 32, tumor luminescence was assessed. The 3 days of dasatinib dosing were sufficient to induce a robust reinvigoration of the anti-tumor response (blue). These data indicate that iterative dosing of dasatinib may reinvigorate exhausted T cells in vivo. -
FIG. 23 : The nucleic acid and amino acid sequence for CD19.28z (FMC63 scFv). -
FIG. 24 : The nucleic acid and amino acid sequence for CD19.BBz (FMC63 scFv). -
FIG. 25 : The nucleic acid and amino acid sequence for GD2.BBz (14G2a scFv). -
FIG. 26 : The nucleic acid and amino acid sequence for HA-GD2.28z (High affinity 14G2a scFv). - It must be noted that, as used in this specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “a T cell” includes two or more T cells, and the like.
- The term “about,” particularly in reference to a given quantity, is meant to encompass deviations of plus or minus five percent.
- The term “chimeric antigen receptor” or “CAR,” as used herein, refers to an artificial T cell receptor that is engineered to be expressed on an immune effector cell and specifically bind an antigen. CARs may be used as a therapy with adoptive cell transfer. T cells are removed from a patient and modified so that they express the receptors specific to a particular form of antigen. In some embodiments, the CARs have been expressed with specificity to a tumor associated antigen, for example. CARs may also comprise an intracellular activation domain, a transmembrane domain and an extracellular domain comprising a tumor associated antigen binding region. The specificity of CAR designs may be derived from ligands of receptors (e.g., peptides). In some embodiments, a CAR can target cancers by redirecting the specificity of a T cell expressing the CAR specific for tumor associated antigens.
- “Pharmaceutically acceptable excipient or carrier” refers to an excipient that may optionally be included in the compositions of the invention and that causes no significant adverse toxicological effects to the patient.
- “Pharmaceutically acceptable salt” includes, but is not limited to, amino acid salts, salts prepared with inorganic acids, such as chloride, sulfate, phosphate, diphosphate, bromide, and nitrate salts, or salts prepared from the corresponding inorganic acid form of any of the preceding, e.g., hydrochloride, etc., or salts prepared with an organic acid, such as malate, maleate, fumarate, tartrate, succinate, ethylsuccinate, citrate, acetate, lactate, methanesulfonate, benzoate, ascorbate, para-toluenesulfonate, palmoate, salicylate and stearate, as well as estolate, gluceptate and lactobionate salts. Similarly, salts containing pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonium (including substituted ammonium).
- The term “T cell” refers to T lymphocytes as defined in the art and is intended to include thymocytes, immature T lymphocytes, mature T lymphocytes, resting T lymphocytes, or activated T lymphocytes. The T cells can be CD4+ T cells, CD8+ T cells, CD4+CD8+ T cells, or CD4−CD8− cells. The T cells can also be T helper cells, such as T helper 1 (TH1), or T helper 2 (TH2) cells, or TH17 cells, as well as cytotoxic T cells, regulatory T cells, natural killer T cells, naïve T cells, memory T cells, or gamma delta T cells.
- The T cells can be a purified population of T cells, or alternatively the T cells can be in a population with cells of a different type, such as B cells and/or other peripheral blood cells. The T cells can be a purified population of a subset of T cells, such as CD4+ T cells, or they can be a population of T cells comprising different subsets of T cells. In another embodiment of the invention, the T cells are T cell clones that have been maintained in culture for extended periods of time. T cell clones can be transformed to different degrees. In a specific embodiment, the T cells are a T cell clone that proliferates indefinitely in culture.
- In some embodiments, the T cells are primary T cells. The term “primary T cells” is intended to include T cells obtained from an individual, as opposed to T cells that have been maintained in culture for extended periods of time. Thus, primary T cells are particularly peripheral blood T cells obtained from a subject. A population of primary T cells can be composed of mostly one subset of T cells. Alternatively, the population of primary T cells can be composed of different subsets of T cells.
- The T cells can be from previously stored blood samples, from a healthy individual, or alternatively from an individual affected with a condition. The condition can be an infectious disease, such as a condition resulting from a viral infection, a bacterial infection or an infection by any other microorganism, or a hyperproliferative disease, such as cancer like melanoma. In yet another embodiment of the invention, the T cells are from a subject suffering from or susceptible to an autoimmune disease or T-cell pathologies. The T cells can be of human origin, murine origin or any other mammalian species.
- “T cell exhaustion” refers to loss of T cell function, which may occur as a result of an infection or a disease. T cell exhaustion is associated with increased expression of PD-1, TIM-3, and LAG-3, apoptosis, and reduced cytokine secretion.
- By “therapeutically effective dose or amount” of an inhibitor of TCR signaling (e.g., dasatinib) is intended an amount that, when administered as described herein, brings about a positive therapeutic response in treatment of T cell exhaustion, such as restored T cell function. Improved T cell function may include decreased expression of PD-1, TIM-3, and LAG-3, maintenance of memory markers (e.g., CD62L or CCR7), prevention of apoptosis, and increased secretion of IL-2 and other cytokines. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, the particular drug or drugs employed, mode of administration, and the like. An appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation, based upon the information provided herein.
- The terms “subject,” “individual,” and “patient,” are used interchangeably herein and refer to any vertebrate subject, including, without limitation, humans and other primates, including non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like. The term does not denote a particular age. Thus, both adult and newborn individuals are intended to be covered.
- The invention is based on the discovery that transient inhibition or modulation of TCR signaling and/or CAR signaling in human T cells can prevent or reverse T cell exhaustion and restore T cell function. The inventors have shown that GD2-CAR expressing T cells develop functional exhaustion, exhibited by expression of PD-1, TIM-3, and LAG-3 exhaustion markers. Cessation of tonic signaling restores the ability of T cells to secrete IL-2 in response to tumor antigen. The inventors further showed that treatment with dasatinib, a Lck tyrosine kinase inhibitor that inhibits T cell receptor signaling, reduced expression of the T cell exhaustion markers and improved preservation of T cell memory.
- Protein tyrosine kinases are a family of enzymes catalysing the transfer of the terminal phosphate of adenosine triphosphate to tyrosine residues in protein substrates. Phosphorylation of tyrosine residues on protein substrates leads to transduction of intracellular signals which regulate a wide variety of intracellular processes such as growth and activation of cells of the immune system, e.g. T-cells. As T-cell activation is implicated in a number of inflammatory conditions and other disorders of the immune system (e.g. autoimmune diseases), modulation of the activity of protein tyrosine kinases appears to be an attractive route to the management of inflammatory diseases. A large number of protein tyrosine kinases have been identified which may be receptor protein tyrosine kinases, e.g. the insulin receptor, or non-receptor protein tyrosine kinases.
- Protein tyrosine kinases of the Src family have been found to be particularly important for intracellular signal transduction related to inflammatory responses (see, e.g., D. Okutani et al., Am. J. Physiol. Lung Cell Mol. Physiol. 291, 2006, pp. L129-L141; CA. Lowell, Mol. Immunol. 41, 2004, pp. 631-643). While some of Src family protein tyrosine kinases, e.g. Src, Yes and Fyn, are expressed in a variety of cell types and tissues, the expression of others is restricted to specific cell types, e.g. hematopoietic cells. Thus, the protein tyrosine kinase Lck is expressed almost exclusively in T-cells as the first signalling molecule to be activated downstream of the T-cell receptor, and its activity is essential for T-cell signal transduction. Expression of Hck, Lyn and Fgr is increased by inflammatory stimuli such as LPS in mature monocytes and macrophages. Also, if gene expression of the main B-cell Src family kinases, namely Lyn, Fyn and BIk, is disrupted, immature B-cells are prevented from developing into mature B-cells. Src family kinases have also been identified as essential for the recruitment and activation of monocytes, macrophages and neutrophils as well as being involved in the inflammatory response of tissue cells.
- As noted, receptor tyrosine kinases are essential components of signal transduction pathways that mediate cell-to-cell communication and their function as relay points for signaling pathways. They have a key role in numerous processes that control cellular proliferation and differentiation, regulate cell growth and cellular metabolism, and promote cell survival and apoptosis. Lck (p56lck or lymphocyte specific kinase) is a cytoplasmic tyrosine kinase of the Src family expressed in T cells and natural killer (NK) cells. Genetic evidence from knockout mice and human mutations demonstrates that Lck kinase activity is critical for T cell receptor (TCR)-mediated signaling, leading to normal T-cell development and activation. As such, selective inhibition of Lck is useful in the treatment of T-cell-mediated autoimmune and inflammatory disorders and/or organ transplant rejection.
- The invention is further based on the discovery that the Lck kinase inhibitor dasatinib and the receptor tyrosine kinase inhibitor ponatinib have the potential to address several important challenges currently facing the field of adoptive T cell therapies (e.g., CART cell therapies). First, these drugs were shown to potently inhibit CAR signaling, which provides a method to regulate CAR activity and thus mitigate CAR T cell toxicity while preserving the option to continue therapy once the toxicity has resolved, as the inhibitory effect of dasatinib and ponatinib on CAR T cell function is reversible. Second, expansion of CAR T cells in the presence of dasatinib or ponatinib was shown to prevent CAR tonic signaling and in turn enhance the functional capacity of CAR T cells. Lastly, providing short periods of CAR T cell “rest” in vivo via iterative drug dosing was shown to be one method by which CAR T cell exhaustion could be prevented or reversed and/or memory could be induced.
- Accordingly, provided herein are compositions and methods for preventing or reversing T cell exhaustion. In particular, the present invention relates to methods of preventing or reversing T cell exhaustion by exposing T cells experiencing T cell exhaustion to particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib), or by expanding genetically engineered T cells in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib).
- As such, the present invention contemplates that exposure of animals (e.g., humans) undergoing adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy) with genetically engineered T cell populations to compositions comprising particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) will result in improved therapy outcome as such particular tyrosine kinase inhibitors are capable of 1) modulating TCR signaling within the genetically engineered T cell population (e.g., decreasing expression of one or more of PD-1, TIM-3, and LAG-3; increasing expression of memory markers (e.g., CD62L or CCR7); increasing secretion of IL-2 and other cytokines), and 2) preventing and/or reversing T cell exhaustion within the genetically engineered T cell population. Indeed, the present invention contemplates that the use of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) (e.g., Src family kinase inhibitors) (e.g., Lck inhibitors) within adoptive T cell therapies satisfies an unmet need as the effectiveness of such therapies are frequently compromised by such T cell populations experiencing T cell exhaustion. Thus, the present invention provides methods for treating an immune system related condition or disease (e.g., cancer) in a subject comprising administering to the subject (e.g., simultaneously and/or at different time points) genetically engineered T cells and particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib). Such methods are not limited to a specific type or kind of genetically engineered T cells. In some embodiments, the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.
- Such tyrosine kinase inhibitors may be administered by any suitable mode of administration, but is typically administered orally. Multiple cycles of treatment may be administered to a subject. In certain embodiments, the tyrosine kinase inhibitors are administered according to a daily dosing regimen or intermittently. In another embodiment, the tyrosine kinase inhibitors are administered for a period of time sufficient to restore at least partial T cell function, then discontinued.
- The present invention contemplates that ex vivo expansion of a population of T cells with particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) will result in a population T cells that are resistant and/or less prone to T cell exhaustion. Thus, the present invention provides compositions comprising a population of T cells that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) (e.g., Src family kinase inhibitors) (e.g., Lck inhibitors). Thus, the present invention provides methods of expanding a population of T cells to generate T cell populations that are resistant and/or less prone to T cell exhaustion through expanding such T cells in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib). Thus, the present invention provides kits comprising T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) and additional agents (e.g., additional agents useful in expanding T cells) (e.g., additional agents useful in adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy). Such methods are not limited to a specific type or kind of genetically engineered T cells. In some embodiments, the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.
- The present invention contemplates that ex vivo expansion of a population of genetically engineered T cells (e.g., genetically engineered for use within adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy)) with particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) (e.g., Src family kinase inhibitors) (e.g., Lck inhibitors) will result in genetically engineered T cells that are resistant and/or less prone to T cell exhaustion. Thus, the present invention provides compositions comprising a population of genetically engineered T cells that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib). Thus, the present invention provides methods of expanding a population of genetically engineered T cells to generate genetically engineered T cell populations that are resistant and/or less prone to T cell exhaustion through expanding such T cells in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib). Thus, the present invention provides kits comprising genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib). Such methods are not limited to a specific type or kind of genetically engineered T cells. In some embodiments, the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.
- The present invention contemplates that exposure of animals (e.g., humans) undergoing adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy) with genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) will result in improved therapy outcome as such genetically engineered T cell populations are resistant and/or less prone to T cell exhaustion. Thus, the present invention provides methods of treating an immune system related condition or disease (e.g., cancer) in a subject comprising administering a population of genetically engineered T cells expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) (e.g., Src family kinase inhibitors) (e.g., Lck inhibitors). Such methods are not limited to a specific type or kind of genetically engineered T cells. In some embodiments, the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.
- Such embodiments are not limited to a particular type or kind of an immune system related condition or disease.
- For example, in some embodiments, the immune system related condition or disease is an autoimmune disease or condition (e.g., Acquired Immunodeficiency Syndrome (AIDS), alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune lymphoproliferative syndrome (ALPS), autoimmune thrombocytopenic purpura (ATP), Behcet's disease, cardiomyopathy, celiac sprue-dermatitis hepetiformis; chronic fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy (CIPD), cicatricial pemphigold, cold agglutinin disease, crest syndrome, Crohn's disease, Degos' disease, dermatomyositis-juvenile, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, Graves' disease, Guillain-Barre syndrome, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), IgA nephropathy, insulin-dependent diabetes mellitus, juvenile chronic arthritis (Still's disease), juvenile rheumatoid arthritis, Meniere's disease, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, pernacious anemia, polyarteritis nodosa, polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, psoriatic arthritis, Raynaud's phenomena, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma (progressive systemic sclerosis (PSS), also known as systemic sclerosis (SS)), Sjogren's syndrome, stiff-man syndrome, systemic lupus erythematosus, Takayasu arteritis, temporal arteritis/giant cell arteritis, ulcerative colitis, uveitis, vitiligo, Wegener's granulomatosis, and any combination thereof).
- For example, in some embodiments, the immune system related condition or disease is cancer (e.g., breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colorectal cancer, renal cancer, liver cancer, brain cancer, lymphoma, leukemia, lung cancer, and thyroid carcinoma).
- The present invention contemplates that the use of genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) within adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy) satisfies an unmet need as such therapies are frequently compromised by such T cell populations experiencing T cell exhaustion. Such methods are not limited to a specific type or kind of genetically engineered T cells. In some embodiments, the genetically engineered T cells include, but are not limited to, CAR T cells, genetically engineered TCR expressing T cells, genetically engineered T cells configured for tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells configured for transduced T-cell therapy, and/or viral specific T cells reengineered with a TCR or CAR.
- The embodiments of the present invention are not limited to specific types of tyrosine kinase inhibitors. In some embodiments, the tyrosine kinase inhibitors are a Lck tyrosine kinase inhibitors. In some embodiments, the tyrosine kinase inhibitor is a Src family kinase inhibitor (e.g., Src kinase inhibitor, Yes kinase inhibitor, Fyn kinase inhibitor, Fgr kinase inhibitor, Lck kinase inhibitor, Hck kinase inhibitor, Blk kinase inhibitor, Lyn kinase inhibitor). In some embodiments, the tyrosine kinase inhibitor is dasatinib
- (N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide), or a pharmaceutically acceptable salt, solvate, or prodrug thereof. In some embodiments, the tyrosine kinase inhibitor is ponatinib
- (3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide), or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
- Some embodiments of the present invention provide for administering such methods (e.g., adoptive T cell therapies with genetically engineered T cell populations and compositions comprising particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib)) (e.g., adoptive T cell therapies with genetically engineered T cell populations that were expanded in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib)) in combination with an effective amount of at least one additional therapeutic agent (including, but not limited to, chemotherapeutic antineoplastics, apoptosis-modulating agents, antimicrobials, antivirals, antifungals, and anti-inflammatory agents) and/or therapeutic technique (e.g., surgical intervention, and/or radiotherapies). In a particular embodiment, the additional therapeutic agent(s) is an anticancer agent.
- Tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) can be formulated into pharmaceutical compositions optionally comprising one or more pharmaceutically acceptable excipients. Exemplary excipients include, without limitation, carbohydrates, inorganic salts, antimicrobial agents, antioxidants, surfactants, buffers, acids, bases, and combinations thereof. Excipients suitable for injectable compositions include water, alcohols, polyols, glycerine, vegetable oils, phospholipids, and surfactants. A carbohydrate such as a sugar, a derivatized sugar such as an alditol, aldonic acid, an esterified sugar, and/or a sugar polymer may be present as an excipient. Specific carbohydrate excipients include, for example: monosaccharides, such as fructose, maltose, galactose, glucose, D-mannose, sorbose, and the like; disaccharides, such as lactose, sucrose, trehalose, cellobiose, and the like; polysaccharides, such as raffinose, melezitose, maltodextrins, dextrans, starches, and the like; and alditols, such as mannitol, xylitol, maltitol, lactitol, xylitol, sorbitol (glucitol), pyranosyl sorbitol, myoinositol, and the like. The excipient can also include an inorganic salt or buffer such as citric acid, sodium chloride, potassium chloride, sodium sulfate, potassium nitrate, sodium phosphate monobasic, sodium phosphate dibasic, and combinations thereof.
- A surfactant can be present as an excipient. Exemplary surfactants include: polysorbates, such as “
Tween 20” and “Tween 80,” and pluronics such as F68 and F88 (BASF, Mount Olive, N.J.); sorbitan esters; lipids, such as phospholipids such as lecithin and other phosphatidylcholines, phosphatidylethanolamines (although preferably not in liposomal form), fatty acids and fatty esters; steroids, such as cholesterol; chelating agents, such as EDTA; and zinc and other such suitable cations. - Acids or bases can be present as an excipient in the pharmaceutical composition. Nonlimiting examples of acids that can be used include those acids selected from the group consisting of hydrochloric acid, acetic acid, phosphoric acid, citric acid, malic acid, lactic acid, formic acid, trichloroacetic acid, nitric acid, perchloric acid, phosphoric acid, sulfuric acid, fumaric acid, and combinations thereof. Examples of suitable bases include, without limitation, bases selected from the group consisting of sodium hydroxide, sodium acetate, ammonium hydroxide, potassium hydroxide, ammonium acetate, potassium acetate, sodium phosphate, potassium phosphate, sodium citrate, sodium formate, sodium sulfate, potassium sulfate, potassium fumerate, and combinations thereof.
- The amount of the tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) (e.g., when contained in a drug delivery system) in the pharmaceutical composition will vary depending on a number of factors, but will optimally be a therapeutically effective dose when the composition is in a unit dosage form or container (e.g., a vial). A therapeutically effective dose can be determined experimentally by repeated administration of increasing amounts of the composition in order to determine which amount produces a clinically desired endpoint.
- The amount of any individual excipient in the pharmaceutical composition will vary depending on the nature and function of the excipient and particular needs of the composition. Typically, the optimal amount of any individual excipient is determined through routine experimentation, i.e., by preparing compositions containing varying amounts of the excipient (ranging from low to high), examining the stability and other parameters, and then determining the range at which optimal performance is attained with no significant adverse effects. Generally, however, the excipient(s) will be present in the composition in an amount of about 1% to about 99% by weight, preferably from about 5% to about 98% by weight, more preferably from about 15 to about 95% by weight of the excipient, with concentrations less than 30% by weight most preferred. These foregoing pharmaceutical excipients along with other excipients are described in “Remington: The Science & Practice of Pharmacy”, 19th ed., Williams & Williams, (1995), the “Physician's Desk Reference”, 52nd ed., Medical Economics, Montvale, N.J. (1998), and Kibbe, A. H., Handbook of Pharmaceutical Excipients, 3rd Edition, American Pharmaceutical Association, Washington, D.C., 2000.
- The pharmaceutical compositions encompass all types of formulations and in particular those that are suited for injection, e.g., powders or lyophilates that can be reconstituted with a solvent prior to use, as well as ready for injection solutions or suspensions, dry insoluble compositions for combination with a vehicle prior to use, and emulsions and liquid concentrates for dilution prior to administration. Examples of suitable diluents for reconstituting solid compositions prior to injection include bacteriostatic water for injection,
dextrose 5% in water, phosphate buffered saline, Ringer's solution, saline, sterile water, deionized water, and combinations thereof. With respect to liquid pharmaceutical compositions, solutions and suspensions are envisioned. Additional preferred compositions include those for oral, ocular, or localized delivery. - The pharmaceutical preparations herein can also be housed in a syringe, an implantation device, or the like, depending upon the intended mode of delivery and use. Preferably, the pharmaceutical compositions comprising one or more tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) described herein are in unit dosage form, meaning an amount of a conjugate or composition of the invention appropriate for a single dose, in a premeasured or pre-packaged form.
- The pharmaceutical compositions herein may optionally include one or more additional agents, or may be combined with one or more additional agents, such as other drugs for treating T cell exhaustion (e.g., anti-PD-1 checkpoint inhibitor, such as nivolumab), or other medications used to treat a subject for an infection or disease associated with T cell exhaustion (e.g., antiviral, antibiotic, or anti-cancer drugs and therapies, including adoptive T cell therapies). Compounded preparations may be used including at least one tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) and one or more other agents, such as other drugs for treating T cell exhaustion or an infection or disease associated with T cell exhaustion. Alternatively, such agents can be contained in a separate composition from the composition comprising a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) and co-administered concurrently, before, or after the composition comprising a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib).
- At least one therapeutically effective cycle of treatment with a tyrosine kinase inhibitor (e.g., a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib)) will be administered to a subject for treatment of T cell exhaustion. By “therapeutically effective cycle of treatment” is intended a cycle of treatment that when administered, brings about a positive therapeutic response with respect to treatment of an individual for T cell exhaustion. Of particular interest is a cycle of treatment with a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) that, when administered transiently as described herein, restores T cell function. For example, a therapeutically effective dose or amount of a tyrosine kinase inhibitor may decrease expression of PD-1, TIM-3, and LAG-3, improve maintenance of memory markers (e.g., CD62L or CCR7), prevent apoptosis, and increase secretion of IL-2 and other cytokines.
- In certain embodiments, multiple therapeutically effective doses of pharmaceutical compositions comprising one or more tyrosine kinase inhibitors (e.g., dasatinib, ponatinib), and/or one or more other therapeutic agents, such as other drugs for treating T cell exhaustion (e.g., anti-PD-1 checkpoint inhibitor, such as nivolumab), or other medications used to treat a subject for an infection or disease associated with T cell exhaustion (e.g., antiviral, antibiotic, or anti-cancer drugs and therapies, including adoptive T cell therapies) will be administered. The pharmaceutical compositions of the present invention are typically, although not necessarily, administered orally, via injection (subcutaneously, intravenously, or intramuscularly), by infusion, or locally. Additional modes of administration are also contemplated, such as topical, intralesion, intracerebral, intracerebroventricular, intraparenchymatous, pulmonary, rectal, transdermal, transmucosal, intrathecal, pericardial, intra-arterial, intraocular, intraperitoneal, and so forth.
- The pharmaceutical preparation can be in the form of a liquid solution or suspension immediately prior to administration, but may also take another form such as a syrup, cream, ointment, tablet, capsule, powder, gel, matrix, suppository, or the like. The pharmaceutical compositions comprising one or more tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) and other agents may be administered using the same or different routes of administration in accordance with any medically acceptable method known in the art.
- In another embodiment, the pharmaceutical compositions comprising one or more tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) and/or other agents are administered prophylactically, e.g., to prevent T cell exhaustion. Such prophylactic uses will be of particular value for subjects with a chronic infection or cancer, who are at risk of developing T cell exhaustion.
- In another embodiment of the invention, the pharmaceutical compositions comprising one or more tyrosine kinase inhibitors (e.g., dasatinib, ponatinib) and/or other agents are in a sustained-release formulation, or a formulation that is administered using a sustained-release device. Such devices are well known in the art, and include, for example, transdermal patches, and miniature implantable pumps that can provide for drug delivery over time in a continuous, steady-state fashion at a variety of doses to achieve a sustained-release effect with a non-sustained-release pharmaceutical composition.
- The invention also provides a method for administering a conjugate comprising a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) as provided herein to a patient suffering from a condition that is responsive to treatment with a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) contained in the conjugate or composition. The method comprises administering, via any of the herein described modes, a therapeutically effective amount of the conjugate or drug delivery system, preferably provided as part of a pharmaceutical composition. The method of administering may be used to treat any condition that is responsive to treatment with a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib). More specifically, the pharmaceutical compositions herein are effective in treating T cell exhaustion.
- Those of ordinary skill in the art will appreciate which conditions a tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) can effectively treat. The actual dose to be administered will vary depending upon the age, weight, and general condition of the subject as well as the severity of the condition being treated, the judgment of the health care professional, and conjugate being administered. Therapeutically effective amounts can be determined by those skilled in the art, and will be adjusted to the particular requirements of each particular case.
- Generally, a therapeutically effective amount will range from about 0.50 mg to 5 grams of a tyrosine kinase inhibitor daily, more preferably from about 5 mg to 2 grams daily, even more preferably from about 7 mg to 1.5 grams daily. Preferably, such doses are in the range of 10-600 mg four times a day (QID), 200-500 mg QID, 25-600 mg three times a day (TID), 25-50 mg TID, 50-100 mg TID, 50-200 mg TID, 300-600 mg TID, 200-400 mg TID, 200-600 mg TID, 100 to 700 mg twice daily (BID), 100-600 mg BID, 200-500 mg BID, or 200-300 mg BID. The amount of compound administered will depend on the potency of the tyrosine kinase inhibitor and the magnitude or effect desired and the route of administration.
- A purified tyrosine kinase inhibitor (again, preferably provided as part of a pharmaceutical preparation) can be administered alone or in combination with one or more other therapeutic agents, such as other drugs for treating T cell exhaustion (e.g., anti-PD-1 checkpoint inhibitor, such as nivolumab), or other medications used to treat a subject for an infection or disease associated with T cell exhaustion (e.g., antiviral, antibiotic, or anti-cancer drugs); or adoptive T cell therapies (e.g., a CAR T-cell therapy, a transduced T-cell therapy, and a tumor infiltrating lymphocyte (TIL) therapy); or other medications used to treat a particular condition or disease according to a variety of dosing schedules depending on the judgment of the clinician, needs of the patient, and so forth. The specific dosing schedule will be known by those of ordinary skill in the art or can be determined experimentally using routine methods. Exemplary dosing schedules include, without limitation, administration five times a day, four times a day, three times a day, twice daily, once daily, three times weekly, twice weekly, once weekly, twice monthly, once monthly, and any combination thereof. Preferred compositions are those requiring dosing no more than once a day.
- A tyrosine kinase inhibitor can be administered prior to, concurrent with, or subsequent to other agents or therapies. If provided at the same time as other agents or therapies, one or tyrosine kinase inhibitors can be provided in the same or in a different composition. Thus, one or more tyrosine kinase inhibitors and other agents can be presented to the individual by way of concurrent therapy. By “concurrent therapy” is intended administration to a subject such that the therapeutic effect of the combination of the substances is caused in the subject undergoing therapy. For example, concurrent therapy may be achieved by administering a dose of a pharmaceutical composition comprising a tyrosine kinase inhibitor and a dose of a pharmaceutical composition comprising at least one other agent, such as another drug for treating T cell exhaustion, which in combination comprise a therapeutically effective dose, according to a particular dosing regimen. Similarly, one or more tyrosine kinase inhibitors and one or more other therapeutic agents can be administered in at least one therapeutic dose. Administration of the separate pharmaceutical compositions or therapies can be performed simultaneously or at different times (i.e., sequentially, in either order, on the same day, or on different days), as long as the therapeutic effect of the combination of these substances is caused in the subject undergoing therapy.
- The invention also provides kits comprising one or more containers holding compositions comprising at least one tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) and optionally one or more other agents for treating T cell exhaustion. Compositions can be in liquid form or can be lyophilized. Suitable containers for the compositions include, for example, bottles, vials, syringes, and test tubes. Containers can be formed from a variety of materials, including glass or plastic. A container may have a sterile access port (for example, the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
- The kit can further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution, or dextrose solution. It can also contain other materials useful to the end-user, including other pharmaceutically acceptable formulating solutions such as buffers, diluents, filters, needles, and syringes or other delivery devices. The delivery device may be pre-filled with the compositions.
- The kit can also comprise a package insert containing written instructions for methods of using the compositions comprising at least one tyrosine kinase inhibitor (e.g., dasatinib, ponatinib) for treating a subject for T cell exhaustion. The package insert can be an unapproved draft package insert or can be a package insert approved by the Food and Drug Administration (FDA) or other regulatory body.
- One of ordinary skill in the art will readily recognize that the foregoing represents merely a detailed description of certain preferred embodiments of the present invention. Various modifications and alterations of the compositions and methods described above can readily be achieved using expertise available in the art and are within the scope of the invention.
- The following examples are illustrative, but not limiting, of the compounds, compositions, and methods of the present invention. Other suitable modifications and adaptations of the variety of conditions and parameters normally encountered in clinical therapy and which are obvious to those skilled in the art are within the spirit and scope of the invention.
- We previously reported that GD2-CAR expressing T cells develop functional exhaustion within 10 days in culture and are characterized by co-expression of inhibitory receptors, failure to secrete cytokines in response to tumor antigen, and aberrant metabolic function (Long et. al, Nat Med 2015). Control cultures included untransduced T cells (mock) and those expressing CD19-CAR, which does not manifest tonic signaling or develop exhaustion in vitro. Previous work also demonstrated that the zeta chain was required for exhaustion in this system, with CD28 signaling enhancing the potency of the signaling stimulus in inducing exhaustion. Using this model system, we have now optimized a robust, manipulatable, and reproducible in vitro human model of T cell exhaustion to evaluate approaches to prevent or reverse T cell exhaustion.
- We engineered a GD2.28z CAR fused to an FKBP12 mutant destabilization domain (Banaszynski et. al, Cell 2006) (GD2.28z.FKBP) which confers its instability to the CAR and induces rapid protein degradation. We observed that surface expression could be rapidly and dose-dependently regulated by adding or subtracting the stabilizing rapalog shield-1 (S1) in culture medium (
FIG. 1 ). Similar regulatability of CAR expression was also accomplished using an E. coli DHFR mutant (GD2.28z.DHFR, not shown), which could be regulated by trimethoprim, an antibiotic that is commonly used clinically. - Since tonic signaling is highly dependent upon GD2-CAR receptor levels, precise control of CAR expression levels also precisely regulates levels of tonic signaling. Drug regulated control of levels of CAR expression therefore also allowed modulation of the duration and intensity of GD2.28z tonic signaling. Using this system, we demonstrated that phenotypic and functional changes associated with exhaustion were reversed upon cessation of CAR signaling. As shown in
FIG. 2 , removal of S1 drug from the culture medium and consequent removal of surface CAR onday 7 post-activation reverses canonical exhaustion marker expression to control levels by day 10 (FIG. 2 , n=3). This is most well illustrated by measuring levels of PD-1/TIM-3/LAG-3 triple expressing cell which is highly specific for dysfunctional, exhausted T cells. We demonstrate thatDay 10 clear induces increases in levels of triple expressing exhausted cells, but that removal of S1 onDay 7 results in normalization of these levels byDay 10. Similar results were obtained onday 14 for cells in which S1 was removed from culture medium onday 7 or day 10 (not shown). - Additionally, removal of S1 on
day day 14 compared to T cells that received S1 for the entire duration of the culture (S1) (FIG. 3 ). - Because phenotypic markers may not be entirely predictive of T cell function, we also performed functional experiments on CAR T cells provided transient drug exposure in culture. CAR T cells were washed, resuspended in media containing S1, and mixed at a 1:1 ratio with Nalm6 leukemic cells stably expressing surface GD2. Culture supernatants were harvested approximately 24 hours later and cytokine levels were evaluated via ELISA. Similar to GD2.28z CAR that lacks a destabilization domain and therefore have persistent high levels of CAR signaling, cells expressing the GD2.28z.FKBP CAR that experienced continuous drug treatment (
FIG. 4 , grey bars) secreted minimal amounts of IL-2 on bothday 10 andday 14 post-activation, consistent with T cell exhaustion. Alternatively, CART cells that were not exposed to drug during culture (black bars) and therefore did not experience tonic signaling demonstrated significant bioactivity as measured by IL-2 production. Finally, CAR T cells that were exposed to drug during the initial 7 or 10 days of culture and therefore acquired phenotypic and functional evidence of T cell exhaustion, but had drug removed from the culture medium onday 7 or day 10 (blue and red bars, respectively) displayed a restored capacity to secrete IL-2 in response to tumor antigen. Remarkably, exhausted T cells on day 10 (grey bar,day 10 ELISA) could be reinvigorated by removing S1 from the culture medium and “rested” for only 4 days (red bar,day 14 ELISA). Similar, but less dramatic augmentation of IFNγ secretion in conditions in which S1 was removed from culture medium was also observed. These functional data cannot be attributed to differential CAR surface expression, as all groups exhibited similar levels of surface CAR at the conclusion of this co-culture assay (not shown). - We then compared whether prevention or reversal of T cell exhaustion by removal of surface CAR was more or less potent than treatment with well-characterized anti-PD-1 checkpoint inhibitor, nivolumab (Nivo). CART cells were either treated with continuous S1 (and thus exhibit continuous tonic signaling), continuous S1+nivolumab, or no S1 until the time of the co-culture assay. Interestingly, nivolumab treatment resulted in only modest augmentation of IL-2 secretion at
day 10, which was sustained untilday 14, suggesting that nivolumab only partially prevented the onset of T cell exhaustion in this system (FIG. 5 ). Conversely, culturing CART cells without S1, then adding it back to the medium just prior to the co-culture assay (left chart, blue bars), resulted in a far superior prevention of exhaustion, as IL-2 secretion was augmented 5-10 fold compared to CART cells that experienced continuous S1 (black bars). Further, removing tonic signaling onday 7 by removing S1 from the culture medium also resulted in superior IL-2 secretion compared to CAR T cells that experienced continuous S1, and those that experienced continuous S1 and were simultaneously treated with S1. Collectively, these data demonstrate that modulating tonic signaling exhibits more potent effects on prevention or reversal of exhaustion compared to PD-1 blockade. - Functional studies by several groups, including our lab have verified that co-expression of PD-1, TIM-3, and LAG-3 (triple positive, TP) denotes an exhausted cell subset that is highly dysfunctional. We thus sought to analyze whether cessation of tonic signaling in this cell subset could reverse their phenotype and restore their ability to secrete IL-2 in response to tumor antigen. A high affinity version of our GD2.28z CAR (HA-GD2.28z), which exhibits an even more dramatic exhausted phenotype, was fused to the FKBP12 mutant destabilization domain in order to control its surface expression. On
day 10 post-activation, HA-GD2.28z.FKBP CAR T cells that had experienced continuous S1 treatment were sorted in order to isolate a pure PD-1/TIM-3/LAG-3 exhausted population. “Triple positive” exhausted cells were then re-cultured either with or without S1 to test whether removal of tonic signaling could restore their function. FACS and co-culture assays were conducted 4 days later. - Removal of S1 resulted in a dramatic reversal of the exhausted phenotype. After only 4 days without S1 in the medium, pre-sorted triple positive cells exhibited far less expression of exhaustion markers in both CD4+ and CD8+ CAR T cells (
FIG. 6 ). Importantly, these phenotypic changes also conferred functional augmentation in IL-2 secretion, as removal of S1 resulted in a 2-fold increase in IL-2 secretion compared to triple positive cells that received continuous S1 treatment from days 10-14 (FIG. 6 ). - We hypothesized that we could recapitulate the effects of removing surface CAR, and thus tonic signaling, by simply inhibiting kinases in the TCR signaling pathway that are also integral to CAR signaling. One such kinase is Lck, which acts to phosphorylate CD3 zeta in response to TCR or CAR ligation. Dasatinib, a potent receptor tyrosine kinase inhibitor and BCR/ABL antagonist, has also been shown to inhibit T cell activation, proliferation, and cytokine secretion by binding to and inhibiting Lck at low concentrations (Schade et. al, Blood, 2008 and Lee et. al, Leukemia, 2010).
- At 100 nM and 1 μM concentrations, dasatinib potently inhibits CD19.28z CART cell cytokine secretion in response to tumor antigen on
day 14 post-activation (FIG. 7 ), proving that dasatinib disrupts CAR signaling. - We then asked whether transient dasatinib exposure could reverse T cell exhaustion by treating HA-GD2.28z CART cells with dasatinib on days 10-14 post-activation. Cells were treated with dasatinib for 4 days, then drug was extensively washed from the media, and cells were re-cultured for an additional 24 hours before examining their phenotype and function via FACS and tumor co-culture assays. Interestingly, 4-day treatment with dasatinib reversed exhaustion marker expression and co-expression in a dose-dependent manner (
FIG. 8 ). - Furthermore, dasatinib treatment resulted in preservation of T cell memory via maintenance of CD62L expression in a dose-dependent manner (
FIG. 9 .). - Finally, similar to removal of surface CAR, dasatinib treatment reinvigorated exhausted T cells in a functionally significant manner, as dasatinib-treated CAR T cells secreted more IL-2 (and to a lesser extent, IFNγ) in response to tumor antigen compared to those that never received dasatinib (
FIG. 10 ). - Collectively, these data demonstrate that selective inhibition or modulation of TCR signaling can substantially enhance the function of exhausted T cells that experience continuous antigen exposure in the context of cancer or chronic infection. In future studies, we will conduct in vivo studies to assess the feasibility of exhaustion reversal in this setting and whether such reversal can enhance antitumor effects in murine models.
- Chimeric antigen receptors (CARs) are synthetic receptors that combine an extracellular tumor-targeting domain with intracellular domains that mimic endogenous TCR signaling (e.g., 1-2 costimulatory domains, like CD28 or 4-1BB, and a CD3 zeta domain) (see, e.g., Lim & June. Cell 168, 724-740 (2017)). When CAR-expressing T cells encounter antigen-expressing tumor cells, CAR T cells form an immune synapse and initiate downstream signaling through the CAR, resulting in potent T cell activation, degranulation of cytotoxic soluble factors, cytokine release, and proliferation. While CAR T cell therapy has experienced unprecedented clinical success in many patients with hematological malignancies, there are several key challenges that must be addressed before this therapy can be expanded to other tumor types or offered as first-line therapy.
- One challenge is CAR toxicity, which typically manifests in the form of cytokine release syndrome (CRS) or on-target off-tumor activity, both of which have been observed in clinical trials and, in some instances, resulted in patient death (see, e.g., Gust et al. Cancer discovery (2017). doi:10.1158/2159-8290.cd-17-0698; Xu & Tang. Cancer Letters 343, 172-178 (2014); D'Aloia, et al. Cell Death & Disease 9, 282 (2018)). Current methods to counteract CAR toxicity are largely limited to a drug-inducible suicide switches (i.e., inducible Caspase 9) that mediate CAR T cell apoptosis (see, e.g., Gargett & Brown. Frontiers in
Pharmacology 5, 235 (2014)). While generally regarded as an effective safety mechanism, utilizing this method eliminates the option to continue therapy after the toxicity event resolves, as the CAR T cells are no longer viable. - A second key challenge to improving the efficacy of CAR T cell therapy is the prevention of CAR T cell exhaustion. T cell exhaustion results from continuous antigen exposure in the context of chronic viral infection or cancer and is characterized by a hierarchical loss of effector function, sustained co-expression of multiple inhibitory receptors (ex., PD-1, TIM-3, LAG-3), attenuated proliferative capacity, and increase apoptosis (see, e.g., Wherry & Kurachi.
Nature Reviews Immunology 15, nri3862 (2015)). There is strong evidence for T cell exhaustion in CART cell therapy. Nearly all CD19.28z CART cells administered disappear byday 60 post-infusion (see, e.g., Lee et al. Long-term outcomes following CD19 CART cell therapy for B-ALL are superior in patients receiving a fludarabine/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation. (2016)). CD19.BBz CART cells, which are thought to be more resistant to T cell exhaustion, also exhibit features of exhaustion and are undetectable in approximately 30% of patients who receive this therapy, consequently increasing the risk of CD19 positive relapse (see, e.g., Turtle et al. Journal of Clinical Investigation 126, 2123-2138 (2016); Maude et al. The New England Journal of Medicine 371, 1507-1517 (2014)). Lastly, exhaustion has also been observed in T cells constitutively expressing CARs that manifest scFv aggregation-induced tonic signaling, which occurs both in the absence of tumor antigen. This unintended consequence of high CAR expression ultimately limits their effectiveness by exhausting CART cells in vitro and in vivo (see, e.g., Long et al. Nature Medicine 21, 581-590 (2015); Gomes-Silva et al. Cell Reports 21, 17-26 (2017)). - Experiments conducted during the course of developing embodiments for the present invention addressed both of these challenges by utilizing FDA-approved small molecule tyrosine kinase inhibitors to modulate CAR T cell activity. Several BCR-Abl inhibitors have been shown to have cross-reactivity with signaling kinases required for T cell activation (see, e.g., Banaszynski, et al.
Nature medicine 14, 1123-7 (2008); Banaszynski, et al. Cell 126, 995-1004 (2006); Iwamoto, et al. Chemistry & Biology 17, 981-988 (2010)). Dasatinib potently inhibits T cell activation and effector functions by inhibiting both Lck and Fyn. Similarly, ponatinib can bind to and inhibit Lck, but does not affect the function of Fyn or Src kinases, suggesting that this drug can also inhibit T cell effector function, and likewise, CAR T cell function. - To test this hypothesis, T cells expressing the CD19-targeting CAR (CD19.28z) were incubated with various concentrations of dasatinib and ponatinib for at least 24 hours. CAR T cells were next co-cultured with antigen-bearing tumor cells for 6 hours in the presence or absence of dasatinib/ponatinib, and subsequently assessed CAR T cell activation and degranulation via CD69 and CD107a co-expression. Nearly 80% of control CART cells were CD69+/CD107a+ upon co-culture with tumor (
FIG. 11a ). Conversely, nanomolar levels of dasatinib and ponatinib potently inhibited activation and degranulation of CAR T cells in a dose-dependent manner (FIG. 11b ). These drugs also potently inhibited CAR T cell IL-2 and IFNγ secretion in response to tumor (FIG. 12 ). Finally, we observed potent inhibition of CAR T cell cytotoxicity when CAR T cells were co-cultured with tumor cells in the presence of 1 uM dasatinib (FIG. 13 ). - To assess whether dasatinib was inhibiting CAR T cell effector function by disrupting CAR signaling, experiments were conducted in which surface CAR were transiently crosslinked on CAR T cells in order to transiently initiate CAR downstream signaling. Under control conditions, cross-linking CAR for 5 minutes induced phosphorylation of the CAR CD3 zeta domain, as well as phosphorylation of distal signaling kinases Akt and Erk1/2 (FIG. 14). Conversely, when CAR T cells were crosslinked in the presence of dasatinib, they resembled non-crosslinked controls, indicating that dasatinib potently disrupted CAR-specific intracellular signaling. Collectively, these experiments indicate that both dasatinib and ponatinib inhibit CAR T cell activity and provide indirect evidence that Lck and/or Fyn are critical for CAR signaling. These experiments also indicate that dasatinib or ponatinib could be utilized clinically to disrupt CAR T cell activity in order to mitigate CAR T cell toxicity.
- As previously mentioned, many constitutively expressed CARs exhibit tonic signaling in the absence of antigen during in vitro expansion, consequently driving them towards T cell exhaustion (see, e.g., Long et al. Nature Medicine 21, 581-590 (2015)). Additional experiments hypothesized that expanding CART cells in the presence of dasatinib or ponatinib would alleviate tonic signaling and consequently yield a healthier, more potent CAR T cell. To test this, T cells expressing a tonically signaling, high-affinity GD2.28z CAR (HA-GD2.28z) were expanded in the presence of various concentrations of dasatinib. Cells were then removed from culture for phenotypic analysis via FACS. Control HA-GD2.28z CART cells exhibited robust single marker expression and co-expression of multiple canonical exhaustion markers (
FIG. 15 ). Conversely, expansion in dasatinib reduced both the frequency of exhaustion-marker co-expressing cells as well as the extent to which these exhaustion markers were expressed in a dose-dependent manner (FIG. 15 ). CART cell expansion in the presence of dasatinib also augmented T cell memory formation, as a nearly 6-fold increase in the frequency of central-memory-like T cells (CD45RA low, CCR7 high) and a greater-than 2-fold reduction in the frequency of effector-memory-like T cells (CD45RA low, CCR7 low) was observed compared to exhausted CAR T cells cultured in the absence of dasatinib. - Experiments next hypothesized that the dramatic phenotypic changes observed when tonic signaling was mitigated by dasatinib or ponatinib may coincide with an augmentation in T cell function. To test this, experiments first expanded tonically signaling CAR T cells in the presence or absence of various concentrations of dasatinib or ponatinib. Experiments next removed the drugs from culture in order to allow CAR T cells to regain the capacity to function. 18-24 hours after removal of drug, the differentially expanded CAR T cells were co-cultured with antigen-bearing tumor cells for 24 hours and subsequently assessed cytokine release via ELISA, or co-cultured for 72 hours and assessed cytotoxicity via incucyte assay. Tonically signaling CAR T cells cultured in the absence of dasatinib or ponatinib secreted low levels of cytokine in response to tumor (
FIG. 17 ) and exhibited impaired cytotoxicity (FIG. 18 ), indicating that these cells were functionally exhausted. Alternatively, expansion of CAR T cells in the presence of dasatinib or ponatinib dose-dependently augmented CAR T cell cytokine secretion (FIG. 17 ) and also allowed for a more potent cytotoxic response (FIG. 18 ), confirming that the mitigation of tonic signaling during CAR T cell expansion with these drugs confers profound functional benefits. - Experiments were conducted that tested whether prevention of CAR tonic signaling in vitro augmented the anti-tumor response in vivo. CAR T cells were expanded with or without 1 uM dasatinib and subsequently infused into NSG mice engrafted with antigen-bearing tumor. In a solid tumor model using the 143B osteosarcoma cell line, both GD2.BBz and HA-GD2.28z CAR T cells grown in the absence of dasatinib failed to control tumor growth (
FIGS. 19 and 20 , respectively). However, CAR T cells expanded in dasatinib allowed for a near complete and lasting eradication of the tumor (FIGS. 19 and 20 ). The same effect was observed in a GD2-overexpressing NALM6 leukemia model in which the tumor burden was more established at the time of CART cell infusion (FIG. 21 ). - Experiments were next conducted to determine whether greater CAR T cell proliferation and/or persistence were a few of the key mechanisms by which in vitro expansion in dasatinib augments the anti-tumor response. To test this, CAR T cells were infused into mice that had been engrafted with antigen-bearing tumor. On
day 14 post-infusion, blood samples were taken from the mice and the number of circulating CAR T cells was assessed via FACS counting beads. Tonically signaling HA-GD2.28z CAR T cells expanded in the absence of dasatinib did not expand and/or persist at levels greater than mice infused with mock untransduced T cells (FIG. 22 ). Conversely, both CD4+ and CD8+ CAR T cells that were grown in the presence of 1 uM dasatinib underwent a profound expansion in vivo and persisted (FIG. 22 ). Collectively, these data indicate that limiting CAR tonic signaling by expanding CAR T cells in dasatinib in vitro augments the in vivo anti-tumor response by increasing the capacity for CAR T cells to expand and persist. - Experiments were next conducted that questioned whether in vivo administration of dasatinib could alter CAR T cell phenotype and function. As a proof-of-concept experiment, CAR T cells were infused into mice that were engrafted with antigen-bearing tumor and subsequently dosed with dasatinib for 3 consecutive days. The mice were then sacrificed and CAR T cell frequency and phenotype assessed in both the blood and the spleen. The dasatinib-treated mouse exhibited a higher frequency of CAR T cells in both tissues (
FIG. 22a, c ) compared to the vehicle-treated mouse, indicating that in vivo dasatinib treatment induced in situ proliferation or persistence. Furthermore, CAR T cells that were recovered from the dasatinib-treated mouse exhibited reduced expression of exhaustion markers PD-1 and LAG-3, reduced expression of CD69 (i.e. lower activation state), and higher expression of the memory marker CD62L (FIG. 22b, d ) compared to the vehicle-treated mouse, all of which are consistent with the phenotypic changes observed upon in vitro treatment with dasatinib (FIG. 15, 16 ). These results demonstrate that in vivo administration of dasatinib mitigates CAR T cell exhaustion phenotype and improves memory formation, and indicates that in vivo dasatinib dosing provides a functional benefit in vivo. - Experiments hypothesized that selective in vivo administration of dasatinib will prevent CAR T cell exhaustion by transiently “resting” CAR T cells that are experiencing chronic antigen stimulation. To test this, CAR T cells were infused into mice that exhibited high tumor burden. On day 27 post-tumor engraftment, the mice were dosed with dasatinib or vehicle for 3 consecutive days, then were not treated for a period of 3 additional days. Subsequent to this treatment regimen, tumor burden was assessed and a profound decrease in tumor size in the dasatinib-treated mouse was observed (
FIG. 22e ). Conversely, the tumor burden in vehicle-treated mouse continued to increase, indicating that the augmentation in anti-tumor response was specific to dasatinib treatment. - In summary, dasatinib and ponatinib have the potential to address several important challenges currently facing the field of adoptive T cell therapies (e.g., CART cell therapies). First, these drugs were shown potently inhibit CAR signaling, which provides a method to regulate CAR activity and thus mitigate CAR T cell toxicity while preserving the option to continue therapy once the toxicity has resolved, as the inhibitory effect of dasatinib and ponatinib on CAR T cell function is reversible. Second, expansion of CAR T cells in the presence of dasatinib or ponatinib was shown to prevent CAR tonic signaling and in turn enhance the functional capacity of CAR T cells. Lastly, providing short periods of CAR T cell “rest” in vivo via iterative drug dosing was shown to be one method by which CAR T cell exhaustion could be prevented or reversed and/or memory could be induced.
- This example describes the materials and methods for Example II.
- NALM6-GL (acute lymphoblastic leukemia line, stably transfected with GFP and luciferase) and NALM6-GL-GD2 (stably transfected to overexpress GD2 synthetase) cell lines were cultured in RPMI-1640. 293T and 143B cell lines were cultured in DMEM (Life Technologies). DMEM and RPMI-1640 were supplemented with 10% heat-inactivated FBS (Gibco, Life Technologies), 10 mM HEPES, 100 U/mL penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine (Gibco, Life Technologies).
- Primary human T cells were obtained from healthy donor buffy coats using a Pan T cell negative selection kit (Miltenyi Biotec). Donor T cells were then aliquoted and stored in Cryostor (StemCell Technologies) in liquid nitrogen. T cells were cultured in AimV (Gibco, Life Technologies) supplemented with 5% heat-inactivated FBS, 10 mM HEPES, 1% glutamax (Gibco, Life Technologies), and 100 u/uL recombinant human IL-2 (Peprotech). Dasatinib (Sigma Aldrich and Adooq Biosciences) or ponatinib (SelleckChem) were cultured at 1 uM unless otherwise specified.
- All retroviral supernatants were produced via transient transfection of the 293GP cell line. Briefly, 293GP cells were transfected via Lipofectamine 2000 (Life Technologies) with the plasmids encoding the CARs and RD114 envelope protein. Supernatants were collected at 48 and 72 hours post-transfection, aliquoted and stored at −80 C.
- Upon thawing, T cells were activated at a 3:1 bead:cell ratio using anti-CD3/anti-CD28-coated magnetic beads (Dynabeads, Thermo Fisher) at a concentration of 1×106 cells/mL. On
days day 4 post-activation, magnetic beads were removed from culture, and T cells were cultured at 0.5×106 cells/mL every day thereafter. Media supplemented with IL-2 and drug was changed every two days. Transduction efficiencies were routinely 70-90% for all CARs. - All samples were analyzed with an LSR Fortessa (BD Bioscience) or a Cytoflex (Beckman Coulter) and data were analyzed using FlowJo. Cells were washed twice with PBS and labelled with stained at 1×106 cells/mL in PBS, followed by two washes with FACS buffer (PBS supplemented with 2% FBS and 0.4% 0.5M EDTA). GD2 CARs were detected with the 14g2a anti-idiotype antibody 1A7. CD19 CARs were detected with the FMC63 anti-idiotype antibody 136.20.1. T cell phenotype was evaluated via: CD4 (OKT4, Biolegend), CD8 (SK1, Biolegend), PD-1 (eBioJ105, eBioscience), TIM-3 (F38-2E2, Biolegend), LAG-3 (3DS223H, eBioscience), CD45RA (L48, BD Biosciences), CCR7 (150503, BD Biosciences), CD62L (DREG-56, BD Biosciences), CD69 (FN50, Biolegend), and CD107a (H4A3, eBioscience). For co-culture assays in which CD107a was assessed, tumor cells and CAR T cells were co-cultured in the presence of 1:1000 monensin (eBioscience) and anti-CD107a for at least 6 hours. All FACS plots displaying CART cell phenotype data were pre-gated on CAR+ cells. For mock-transduced T cells, whole T cell populations were used for analysis.
- 50,000 NALM6-GL or NALM6-GL-GD2 tumor cells were co-cultured with T cells at a 1:8 E:T ratio in 200 uL of complete AimV medium without IL-2 supplementation in each well of a 96-well plate. Plates were loaded into the incucyte and 488 nm fluorescent images were acquired every 2 hours for 48-72 hours. GFP+ tumor cells were identified by size and fluorescence intensity masks, and the total integrated GFP intensity of all counted tumor cells was quantified for each individual well. Values were normalized to t=0, and replicate wells were averaged for data display.
- For experiments in which HA-GD2.28z T cells were expanded in the presence of dasatinib, in some instances, drug was removed from the media 18-24 hours prior to the assay to allow CAR T cells to function in the presence of tumor antigen.
- 50,000 NALM6-GL-GD2 tumor cells were co-cultured with T cells at a 1:1 E:T ratio in 200 uL of complete AimV medium without IL-2 supplementation in each well of a 96-well plate. After 24 hours, supernatants were removed and stored at −20 C. IL-2 and IFNγ secretion was assessed via ELISA (Biolegend).
- For experiments in which HA-GD2.28z T cells were expanded in the presence of dasatinib, in some instances, drug was removed from the media 18-24 hours prior to the assay to allow CAR T cells to function in the presence of tumor antigen.
- 2×106 CAR′ cells were removed from culture, pelleted, and resuspended in 100 uL of RITA lysis buffer (10 mM Tris-Cl pH 8.0, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl) supplemented with phosphatase and protease inhibitors (Thermo Fisher), After incubating for 30 minutes at 4 C, supernatants were cleared by centrifugation at 14,000 RPM for 20 minutes at 4 C. Protein concentration in the cleared lysates was measured by a colorimetric reaction (BioRad).
- 1.5 ug of protein lysate was mixed with 6× loading buffer and loaded onto 10% SDS-PAGE gels assembled into a mini-protean electrophoresis systems (BioRad). Electrophoresis was performed in tris-glycine-SDS buffer (BioRad) at 100V for 20 minutes and later increased to 150V for 50 minutes. Protein transfer into Immbilon-FL PVDF membranes was performed at 100V for 1 hour in tris-glycine buffer (BioRad #1610771). Primary antibodies targeting CD3-zeta (Cell signaling), pY142-CD3-zeta (Cell Signaling), p44/42 MAPK (Erk1/2, Cell Signaling), p-p44/42 MAPK (p-ERK1/2, Cell Signaling), pSer473-Akt (D9E, Cell Signaling), and pan Akt (40D4, Cell Signaling) were used. The Odyssey (LI-COR) imaging system. LI-COR buffers, and LI-COR secondary antibodies (Goat Anti-Mouse IgG Antibody-800CW-Conjugated and Goat Anti-Rabbit IgG Antibody-680LT-Conjugated) were used for protein detection.
- For CAR crosslinking, CAR T cells were incubated in 5 ug/mL anti-idiotype (clone 1A7) plus 5 ug/mL goat anti-mouse Fab secondary (Jackson Immunoresearch) or secondary alone for 5 minutes at 37 C. Cells were then quenched in ice cold PBS, pelleted at 4 C for 5 minutes, then lysed for western blot analysis.
- In vivo experiments 6-8 week old NSG mice were engrafted with 1×106 NALM6-GL-GD2 leukemia cells via intravenous injection. At
day 4 post-engraftment, 2×106 HA-GD2.28z CAR+ T cells were infused intravenously. NALM6-GL-GD2 tumor burden was evaluated using the Xenogen IVIS Lumina (Caliper Life Sciences). Mice were first injected intraperitoneally with 3 mg D-luciferin (Caliper Life Sciences) and then imaged 4 minutes later with an exposure time of 30 seconds, or, in cases where 30 seconds resulted in signal saturation, “auto” exposure was selected. Luminescence images were analyzed using Living Image software (Caliper Life Sciences). - 6-8 week old NSG mice were engrafted with 0.5×106 143 B osteosarcoma cells intramuscularly. On
day 3 post-engraftment, 10×106 GD2.BBz or HA-GD2.28z were infused intravenously. Osteosarcoma burden was quantified via two-dimensional leg area measurements. - Mice treated with dasatinib (Adooq Biosciences) were injected intraperitoneally at a concentration of 50 mg/kg in water+10% Kolliphor HS 15 (Sigma Aldrich). Mice treated with vehicle were injected with an equivalent volume of water+10
% Kolliphor HS 15. - Blood samples were taken via retro-orbital bleed and briefly stored in EDTA-coated microvettes (Kent Scientific). Spleens were mechanically disaggregated by passage through a 70-μm filter (BD Biosciences). Both blood and spleen were lysed in ACK lysis buffer (Fisher Scientific) for 5 minutes and subsequently stained with surface marker antibodies for FACS analysis.
- All CAR sequences were inserted into the MSGV retroviral backbone. Each CAR includes a signal peptide, single chain variable fragment (scFv), extracellular hinge region, transmembrane domain, intracellular co-stimulatory domain, and intracellular CD3 zeta domain.
- The nucleic acid and amino acid sequence for CD19.28z (FMC63 scFv) is provided at
FIG. 23 . - The nucleic acid and amino acid sequence for CD19.BBz (FMC63 scFv) is provided at
FIG. 24 . - The nucleic acid and amino acid sequence for GD2.BBz (14G2a scFv) is provided at
FIG. 25 . - The nucleic acid and amino acid sequence for HA-GD2.28z (High affinity 14G2a scFv) is provided at
FIG. 26 . - Having now fully described the invention, it will be understood by those of skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations, and other parameters without affecting the scope of the invention or any embodiment thereof. All patents, patent applications and publications cited herein are fully incorporated by reference herein in their entirety.
- The entire disclosure of each of the patent documents and scientific articles referred to herein is incorporated by reference for all purposes.
- The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.
Claims (57)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/499,762 US20200101108A1 (en) | 2017-03-31 | 2018-03-30 | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762479930P | 2017-03-31 | 2017-03-31 | |
US16/499,762 US20200101108A1 (en) | 2017-03-31 | 2018-03-30 | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
PCT/US2018/025394 WO2018183842A1 (en) | 2017-03-31 | 2018-03-30 | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200101108A1 true US20200101108A1 (en) | 2020-04-02 |
Family
ID=63677091
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/499,760 Active 2040-10-15 US11938153B2 (en) | 2017-03-31 | 2018-03-30 | Methods of treating T cell exhaustion by inhibiting or modulating T cell receptor signaling |
US16/499,762 Pending US20200101108A1 (en) | 2017-03-31 | 2018-03-30 | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/499,760 Active 2040-10-15 US11938153B2 (en) | 2017-03-31 | 2018-03-30 | Methods of treating T cell exhaustion by inhibiting or modulating T cell receptor signaling |
Country Status (7)
Country | Link |
---|---|
US (2) | US11938153B2 (en) |
EP (2) | EP3600323A4 (en) |
JP (4) | JP7249287B2 (en) |
CN (2) | CN110582280B (en) |
AU (2) | AU2018243664B2 (en) |
CA (2) | CA3057505A1 (en) |
WO (2) | WO2018183842A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022094314A1 (en) * | 2020-10-30 | 2022-05-05 | The University Of North Carolina At Chapel Hill | Dual targeting chimeric antigen receptors |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3084873A1 (en) * | 2017-12-07 | 2019-06-13 | Julius-Maximilians-Universitat Wurzburg | Control and modulation of the function of gene-modified chimeric antigen receptor t cells with dasatinib and other tyrosine kinase inhibitors |
WO2020092650A1 (en) * | 2018-10-30 | 2020-05-07 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating t cell exhaustion |
JP2022512971A (en) * | 2018-11-08 | 2022-02-07 | ジュノー セラピューティクス インコーポレイテッド | Methods and combinations for treatment and T cell regulation |
WO2020180243A1 (en) * | 2019-03-01 | 2020-09-10 | National University Of Singapore | Engineered immune cells |
CN110157680A (en) * | 2019-05-08 | 2019-08-23 | 浙江大学 | Improve the cell culture processes of Chimeric antigen receptor T cell curative effect and duration of action |
JPWO2021020564A1 (en) * | 2019-08-01 | 2021-02-04 | ||
PE20230435A1 (en) * | 2020-06-19 | 2023-03-08 | Chugai Pharmaceutical Co Ltd | ANTI-T CELL ANTIGEN BINDING MOLECULES TO BE USED IN COMBINATION WITH AN ANGIOGENESIS INHIBITOR |
JPWO2022210487A1 (en) * | 2021-03-29 | 2022-10-06 | ||
EP4071248A1 (en) | 2021-04-07 | 2022-10-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Means and methods for enhancing receptor-targeted gene transfer |
EP4334443A1 (en) * | 2021-05-07 | 2024-03-13 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Method for constitutive malt1 protease activation |
CN113533729A (en) * | 2021-06-15 | 2021-10-22 | 北京大学人民医院 | Research method for identifying NK cell depletion in AML patient bone marrow and application thereof |
IL309957A (en) | 2021-07-14 | 2024-03-01 | 2Seventy Bio Inc | Engineered t cell receptors fused to binding domains from antibodies |
US20230310605A1 (en) | 2021-10-28 | 2023-10-05 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing ror1-binding protein |
WO2023077032A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing c-jun |
WO2023196997A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
WO2023244511A2 (en) * | 2022-06-13 | 2023-12-21 | The Regents Of The University Of California | Improved glycan-dependent chimeric antigen receptor cells |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190112380A1 (en) * | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
US20200181573A1 (en) * | 2016-12-05 | 2020-06-11 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
US20210393628A1 (en) * | 2018-10-30 | 2021-12-23 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating t cell exhaustion |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057294A (en) | 1995-01-16 | 2000-05-02 | Northern Sydney Area Health Service Of Pacific Highway | Peptide |
US20050070478A1 (en) | 1996-06-11 | 2005-03-31 | Northern Sydney Area Health Services | T cell antigen receptor peptides |
US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
GB0523954D0 (en) | 2005-11-24 | 2006-01-04 | Ucb Celltech | Bioassays |
US9334330B2 (en) | 2006-10-10 | 2016-05-10 | Universite De Nantes | Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers |
US8173792B2 (en) * | 2007-02-09 | 2012-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells using synthetic small molecules |
EP2664916B1 (en) | 2007-04-02 | 2017-02-08 | Acoustic Cytometry Systems, Inc. | Method for manipulating a fluid medium within a flow cell using acoustic focusing |
WO2012033885A1 (en) | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
PT3214091T (en) | 2010-12-09 | 2019-01-11 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
CN103596981B (en) | 2011-04-08 | 2017-06-16 | 美国卫生和人力服务部 | Anti-epidermal growth factor receptor variant III Chimeric antigen receptors and its purposes for treating cancer |
SG193553A1 (en) | 2011-05-24 | 2013-10-30 | Biontech Ag | Individualized vaccines for cancer |
RU2644243C2 (en) | 2011-10-20 | 2018-02-08 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Chimeric antigenic receptors to cd22 |
CA2857687C (en) * | 2011-12-02 | 2019-07-09 | Stillwater Mining Company | Quantitative precious metals recovery in the presence of interfering metals, salts, and ions |
CN104379179A (en) | 2012-04-11 | 2015-02-25 | 美国卫生和人力服务部 | Chimeric antigen receptors targeting b-cell maturation antigen |
WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
CN110423282B (en) | 2013-02-15 | 2023-09-08 | 加利福尼亚大学董事会 | Chimeric antigen receptor and methods of use thereof |
ES2760023T3 (en) | 2013-02-20 | 2020-05-12 | Univ Pennsylvania | Cancer treatment using humanized anti-EGFRvIII chimeric antigen receptor |
US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
WO2014160627A1 (en) | 2013-03-25 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd276 polypeptides, proteins, and chimeric antigen receptors |
KR102452767B1 (en) | 2013-05-14 | 2022-10-12 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Human application of engineered chimeric antigen receptor (car) t-cells |
US9636340B2 (en) * | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
GB201403972D0 (en) * | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
CN106535925A (en) * | 2014-05-23 | 2017-03-22 | 佛罗里达大学研究基金会有限公司 | CAR based immunotherapy |
JP2017522311A (en) * | 2014-07-16 | 2017-08-10 | ジェネンテック, インコーポレイテッド | Method for treating cancer using TIGIT inhibitor and anticancer agent |
TWI719942B (en) | 2014-07-21 | 2021-03-01 | 瑞士商諾華公司 | Treatment of cancer using a cd33 chimeric antigen receptor |
US20170226216A1 (en) | 2014-07-24 | 2017-08-10 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
CN112410363A (en) | 2014-08-19 | 2021-02-26 | 诺华股份有限公司 | anti-CD 123 Chimeric Antigen Receptor (CAR) for cancer therapy |
WO2016061368A1 (en) | 2014-10-15 | 2016-04-21 | The Children's Hospital Of Philadelphia | Compositions and methods for treating b-lymphoid malignancies |
GB201500319D0 (en) * | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
WO2016134284A1 (en) * | 2015-02-19 | 2016-08-25 | University Of Florida Research Foundation, Inc. | Chimeric antigen receptors and uses thereof |
EP3270936A4 (en) * | 2015-03-17 | 2018-08-08 | Chimera Bioengineering Inc. | Smart car devices, de car polypeptides, side cars and uses thereof |
GB201514328D0 (en) * | 2015-08-12 | 2015-09-23 | Sigmoid Pharma Ltd | Compositions |
WO2017127755A1 (en) | 2016-01-20 | 2017-07-27 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
WO2017181119A2 (en) | 2016-04-15 | 2017-10-19 | Novartis Ag | Compositions and methods for selective protein expression |
CA3084873A1 (en) | 2017-12-07 | 2019-06-13 | Julius-Maximilians-Universitat Wurzburg | Control and modulation of the function of gene-modified chimeric antigen receptor t cells with dasatinib and other tyrosine kinase inhibitors |
-
2018
- 2018-03-30 CN CN201880028993.XA patent/CN110582280B/en active Active
- 2018-03-30 CA CA3057505A patent/CA3057505A1/en active Pending
- 2018-03-30 AU AU2018243664A patent/AU2018243664B2/en active Active
- 2018-03-30 WO PCT/US2018/025394 patent/WO2018183842A1/en active Application Filing
- 2018-03-30 WO PCT/US2018/025459 patent/WO2018183888A2/en active Application Filing
- 2018-03-30 EP EP18775932.9A patent/EP3600323A4/en active Pending
- 2018-03-30 JP JP2019553214A patent/JP7249287B2/en active Active
- 2018-03-30 AU AU2018243571A patent/AU2018243571B2/en active Active
- 2018-03-30 EP EP18777667.9A patent/EP3600357A4/en active Pending
- 2018-03-30 CN CN201880029045.8A patent/CN110603044A/en active Pending
- 2018-03-30 CA CA3057372A patent/CA3057372A1/en active Pending
- 2018-03-30 US US16/499,760 patent/US11938153B2/en active Active
- 2018-03-30 JP JP2019553220A patent/JP7278961B2/en active Active
- 2018-03-30 US US16/499,762 patent/US20200101108A1/en active Pending
-
2022
- 2022-12-02 JP JP2022193805A patent/JP2023025187A/en active Pending
-
2023
- 2023-01-27 JP JP2023011257A patent/JP2023055805A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190112380A1 (en) * | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
US20200181573A1 (en) * | 2016-12-05 | 2020-06-11 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
US20210393628A1 (en) * | 2018-10-30 | 2021-12-23 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating t cell exhaustion |
Non-Patent Citations (4)
Title |
---|
Araujo et al., Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors, Cancer Treatment Review 36(2010): 492-500, Publication Year: 2010 (Year: 2010) * |
Chames et al., Therapeutic antibodies: successes, limitations and hopes for the future, British J. of Pharmacology, 2009, 157, 220-233 (Year: 2009) * |
Gura, T., Systems for Identifying New Drugs Are Often Faulty, Science, 1997, 278:1041-1042 (Year: 1997) * |
Kaiser, J., First pass at cancer genoome reveals complex landscape, Science, 2006, 313:1370 (Year: 2006) * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022094314A1 (en) * | 2020-10-30 | 2022-05-05 | The University Of North Carolina At Chapel Hill | Dual targeting chimeric antigen receptors |
Also Published As
Publication number | Publication date |
---|---|
US11938153B2 (en) | 2024-03-26 |
CN110582280A (en) | 2019-12-17 |
JP7278961B2 (en) | 2023-05-22 |
JP2020515259A (en) | 2020-05-28 |
US20210032363A1 (en) | 2021-02-04 |
EP3600357A4 (en) | 2021-01-06 |
JP2023055805A (en) | 2023-04-18 |
AU2018243664A1 (en) | 2019-10-17 |
AU2018243664B2 (en) | 2024-02-01 |
CN110582280B (en) | 2024-03-19 |
WO2018183888A2 (en) | 2018-10-04 |
WO2018183888A3 (en) | 2018-11-08 |
JP2020515581A (en) | 2020-05-28 |
JP7249287B2 (en) | 2023-03-30 |
EP3600357A2 (en) | 2020-02-05 |
CA3057505A1 (en) | 2018-10-04 |
WO2018183842A1 (en) | 2018-10-04 |
EP3600323A1 (en) | 2020-02-05 |
CN110603044A (en) | 2019-12-20 |
CA3057372A1 (en) | 2018-10-04 |
EP3600323A4 (en) | 2020-11-11 |
AU2018243571B2 (en) | 2024-03-07 |
JP2023025187A (en) | 2023-02-21 |
AU2018243571A1 (en) | 2019-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018243571B2 (en) | Methods of treating T cell exhaustion by inhibiting or modulating T cell receptor signaling | |
JP6748221B2 (en) | Alternative to cytotoxic preconditioning prior to cellular immunotherapy | |
KR20180134419A (en) | Compositions and methods for cellular immunotherapy | |
ES2704272T3 (en) | Combined preparations for the treatment of cancer or infection | |
CN110958888A (en) | CD47 blocking therapy | |
CN117100753A (en) | Use of Plinabulin in combination with immune checkpoint inhibitors | |
CN102946867A (en) | Compoisitons comprising polyglutamic acid nanoparticles and polypeptides such as cd40 agonists | |
KR20230027322A (en) | Cancer-targeted il-12 immunotherapy | |
US11446314B2 (en) | Immunoablative therapies | |
JP2020105219A (en) | Improved cell compositions and methods for cancer therapy | |
JP2023507190A (en) | Use of anti-TGFβ antibodies and checkpoint inhibitors to treat proliferative diseases | |
US20220008515A1 (en) | Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor | |
US20210393628A1 (en) | Compositions and methods for modulating t cell exhaustion | |
WO2023056346A1 (en) | Engineered nk cells and uses thereof | |
Weltz et al. | Mechanisms of Immunosuppressive Drugs | |
CN112955188A (en) | Method of treating neuroendocrine tumors | |
US20230265149A1 (en) | Encapsulated cells expressing il-2 and uses thereof | |
US20240000883A1 (en) | Method of sensitizing cancers to immunotherapy using immunomodulatory agents | |
WO2023083439A1 (en) | Tlr7 agonist and combinations for cancer treatment | |
JP2024515211A (en) | Augmentation of CD47 blockade therapy with DHFR inhibitors | |
WO2021127557A1 (en) | Compositions and methods for treatment of headache disorders and neuropathic pain | |
EA043659B1 (en) | IMMUNOABLATIVE THERAPIES | |
EA043393B1 (en) | REPLACEMENT OF CYTOTOXIC PRECONDITIONING BEFORE CELLULAR IMMUNOTHERAPY | |
Pidala et al. | IL-12/23p40 Neutralization in Combination with Sirolimus for Prevention of Acute Graft Vs. Host Disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LYNN, RACHEL;MACKALL, CRYSTAL;MALHOTRA, SANJAY;AND OTHERS;SIGNING DATES FROM 20180426 TO 20180618;REEL/FRAME:052125/0309 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |